Peptides having anti-melittin activity
专利汇可以提供Peptides having anti-melittin activity专利检索，专利查询，专利分析的服务。并且Disclosed are peptides having anti-mellitin activity and having the formulae AC-IVILZZ-NH.sub.2, wherein Z is an amino acid. Also disclosed are compositions containing these peptides and methods of using them.，下面是Peptides having anti-melittin activity专利的具体信息内容。
We claim:1. A peptide having anti-melittin activity of IC.sub.50 less than 30 .mu.gms/ml and having the formula Ac-IVILZZ-NH.sub.2 (SEQ ID NO:8), Ac-IVILTZ-NH.sub.2 (SEQ ID NO: 9), Ac-IVILLZ-NH.sub.2 or Ac-IVIFFZ-NH.sub.2, (SEQ ID NO: 11), wherein Z is selected from the group consisting of a naturally occurring amino acid, a D-amino acid, a methylated naturally occurring amino acid, a methylated D-amino acid, a chlorinated naturally occurring amino acid, and chlorinated D-amino acid. 2. A peptide having anti-melittin activity of IC.sub.50 less than 30 .mu.gms/ml and having the formula Ac-IVILZZ-NH.sub.2 (SEQ ID NO: 8), Ac-IVILTZ-NH.sub.2 (SEQ ID NO: 9), Ac-IVILLZ-NH.sub.2 or Ac-IVIFFZ-NH.sub.2, (SEQ ID NO: 11), wherein Z is a naturally occurring amino acid. 3. A peptide having anti-melittin activity of IC.sub.50 less than 30 .mu.gms/ml and having the formula Ac-Z.sub.1 Z.sub.2 IZ.sub.3 Z.sub.4 Z.sub.5 -NH.sub.2 �SEQ ID NO: 12!, wherein Z.sub.1 is F or I; Z.sub.2 is I or Q; Z.sub.3 is W or Y; Z.sub.4 is C or F and Z.sub.5 is E. 4. A peptide selected from the group consisting of peptides having the formula Ac-MILWIE-NH.sub.2 (SEQ ID NO: 13), Ac-VIQQFV-NH.sub.2 (SEQ ID NO: 14) and Ac-WIQIFI-NH.sub.2 (SEQ ID NO: 15). 5. A composition comprising a peptide of any of claims 1, 3 or 4, in an acceptable carrier. 6. A pharmaceutical composition comprising a peptide of any of claims 1, 3 or 4 in a pharmaceutically acceptable carrier. 7. A method of treating a subject suffering from cell lysis resulting from melittin poisoning comprising the step of administering to the subject a therapeutically effective count of a pharmaceutical composition of claim 6. 8. A method of treating a subject suffering from an allergenic response resulting from melittin poisoning comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 6.
This application is a divisional of application Ser. No. 08/079,445, filed Jun. 18, 1993, now U.S. Pat. No. 5,440,016.
BACKGROUND OF THE INVENTION
This invention relates to the field of biologically active peptides and, in particular to peptides having anti-microbial activity, hemolytic activity, anti-melittin activity or anti-enzymatic activity.
Melittin, a 26-residue peptide, is the predominant compound isolated from honey bee venom (Apis mellifera). Melittin is known for its marked cytolytic activities, as well as for its allergenic properties. Earlier studies using individual peptide analogues of melittin (Peptide Research 4(1): 12-18, 1991; Biochemistry 30(19): 4671-4678, 1991), showed that the initial step of the mechanism of melittin's hemolytic activity involves interactions and/or binding between melittin and the lipid groups of the membrane. Compounds which would inhibit these interactions and/or bindings, would prevent the allergenic and/or lytic action of melittin in the bee venom. Furthermore, the generation of such a compound would give insight into the mechanism of action of melittin in its lytic activity.
Recent advances in technology have provided methods for the preparation and screening of a large mumber of individual peptides. Peptides identified in this manner have included peptides binding to antibody combining sites, among other things. There is a need in the art for peptides that have useful levels of anti-microbial activity, hemolytic activity, anti-melittin activity or anti-enzymatic activity. This invention satisfies these needs by providing such bio-active peptides.
SUMMARY OF THE INVENTION
This invention provides peptides having anti-microbial activity and having the formula (KFmoc)ZZZ-NH2 SEQ ID NO: 1!, wherein Z is an amino acid; compositions having the aforementioned peptide in an acceptable carrier; and pharmaceutical compositions having the aforementioned peptide in a pharmaceutically acceptable carrier wherein the peptide has HD50 greater than 100 μgms/ml. This invention also provides methods of treating a subject having a microbial infection having the step of administering to the subject a therapeutically effective amount of the aforementioned pharmaceutical composition. This invention also provides methods of inhibiting the growth of a microorganism having the step of contacting the microorganism with an effective amount of an aforementioned anti-microbial peptide. This invention also provides methods of lysing red blood cells having the step of contacting red blood cells with an effective amount of an aforementioned peptide.
This invention provides compositions having a peptide having anti-microbial activity and having the formula Ac-RRWWCZ-NH2, wherein Z is an amino acid; compositions having the aforementioned peptide in an acceptable carrier; and pharmaceutical compositions having the aforementioned peptide wherein the peptide has HD50 greater than 100 μgms/ml, in a pharmaceutically acceptable carrier. This invention also provides methods of treating a subject infected with a gram negative bacterium or yeast having the step of administering to the subject a therapeutically effective amount of the aforementioned pharmaceutical composition. This invention provides methods of inhibiting the growth of a gram negative bacteria or yeast having the step of contacting the gram negative bacteria or yeast with an effective amount of the aforementioned peptide.
This invention provides anti-microbial peptides having the formula Ac-rrwwcz-NH2, wherein z is a D-amino acid; compositions having the aforementioned peptide in an acceptable carrier; and pharmaceutical compositions having the aforementioned peptide in a pharmaceutically acceptable carrier and having HD50 greater than 100 μgms/ml. This invention also provides methods of treating a subject having a microbial infection having the step of administering to the subject a therapeutically effective amount of the aforementioned pharmaceutical composition, methods of inhibiting the growth of a microorganism having the step of contacting the microorganism with an effective amount of the aforementioned peptide; and methods of lysing red blood cells having the step of contacting red blood cells with an effective amount of the aforementioned peptide having HD50 less than 100 μgms/ml;
This invention provides peptides having anti-melittin activity and having the formula Ac-IVILTZ-NH2 SEQ ID NO: 9!, Ac-IVILLZ-NH2 SEQ ID NO: 10! or Ac-IVIFFZ-NH2 SEQ ID NO: 11!, wherein Z is an amino acid; and Ac-Z1 Z2 IZ3 Z4 Z5 -NH2 SEQ ID NO: 12!, wherein Z1, Z2, Z3, Z4 and Z5 are amino acids; Ac-MILWIE-NH2 SEQ ID NO: 13!, Ac-VIQQFV-NH2 SEQ ID NO: 14! and Ac-WIQIFI-NH2 SEQ ID NO: 15!; compositions having any of the aforementioned peptides in an acceptable carrier; and pharmaceutical compositions having any of the aforementioned peptides in a pharmaceutically acceptable carrier wherein the peptides has IC50 less than 30 μgms/ml. This invention also provides methods of inhibiting melittin activity having the step of contacting melittin with an effective amount of any of the aforementioned peptides; and methods of treating a subject suffering from melittin poisoning having the step of administering to the subject a therapeutically effective amount of the aforementioned pharmaceutical composition.
This invention provides peptides having the formula Ac-ryrpwz-NH2, wherein z a D-amino acid, said peptide having an IC50 less than 150 μM against trypsin. This invention provides methods of inhibiting trypsin activity having the step of contacting trypsin with an effective amount of the aforementioned peptide.
DETAILED DESCRIPTION OF THIS INVENTION
This invention provides peptides having anti-microbial activity. These peptides inhibit the growth of microorganisms. This invention also provides peptides with high hemolytic activity. These peptides cause the lysis of red blood cells. This invention also provides peptides with anti-melittin activity. These peptides inhibit the ability of melittin to lyse red blood cells. This invention also provides peptides having anti-trypsin activity. These peptides inhibit the protolyptic action of trypsin. The disclosure of U.S. Pat. No. 4,631,211 is incorporated herein by reference.
As used herein, the term "amino acid" refers both to the naturally occurring amino acids and their derivatives, such as TyrMe and PheCl, as well as other moieties characterized by the presence of both available carboxyl group and amine group. Non-amino acid moieties which can be contained in such peptides include, for example, amino acid mimicking structures. Mimicking structures are those structures which exhibit substantially the same spatial arrangement of functional groups as amino acids but do not necessarily have both the α-amino and α-carboxyl groups characteristic of amino acids.
This invention provides generic peptides having a formula wherein "Z" designates an amino acid as defined above. According to certain embodiments of this invention, Z is an amino acid specified in Table 1; an L-amino acid; one of the twenty naturally occuring L-amino acids; a D-amino acid; or a D-amino acid version of one of the twenty naturally occuring L-amino acids.
Table 1 presents a list of amino acids referred to herein. The first column of lists abbreviations for amino acids as used in this specification. The second column lists amino acid abbreviations set forth in 37 C.F.R. § 1.822. The third column lists amino acids by name.
TABLE 1______________________________________Spec 37 C.F.R § 1.822Abbreviation Abbreviation Name______________________________________A Ala L-AlanineR Arg L-ArginineN Asn L-AsparagineD Asp L-Aspartic AcidC Cys L-CysteineE Glu L-Glutamic AcidQ Gln L-GlutamineG, g Gly GlycineH His L-HistidineI Ile L-IsoleucineL Leu L-LeucineK Lys L-LysineM Met L-MethionineF Phe L- PhenylalanineP Pro L-ProlineS Ser L-SerineT Thr L-ThreonineW Trp L-TryptophanY Tyr L-TyrosineV Val L-ValineZ, z Xaa Specified amino acidX Equimolar mixture of specified amino acidsa D-Alaniner D-Argininen D-Asparagined D-Aspartic Acidc D-Cysteinee D-Glutamic Acidq D-Glutamineh D-Histidinei D-Isoleucinel D-Leucinek D-Lysinem D-Methioninef D- Phenylalaninep D-Prolines D-Serinet D-Threoninew D-Tryptophany D-Tyrosinev D-ValineBala bAla beta-alanineaABA Abu alpha-amino butyric acidgABA 4Abu gamma-amino butyric acidaAIB Aib alpha-amino isobutyric acideAca Acp epsilon-amino caproic acidbAsp Beta-aspartic acidgGlu gamma-glutamic acidCys (ACM) cysteine (ACM)KCBZ epsilon-lysineKFmoc epsilon-lysine (a-Fmoc)MetO2 methionine sulfoneNle norleucineNve norvalineOrn Orn ornithinedOrn delta- ornithineNO2 F p-nitro- phenylalanineHyp 3Hyp hydroxyprolineThiopro thioproline7aHa 7-amino heptanoic acid______________________________________
As used herein, Ac- is an acetyl group of an acetylated amino-terminal amino acid of the formula: ##STR1## wherein R is the side chain.
As used herein, NH2 is the amido group of an amidated, carboxy-terminal amino acid residue of the formula: ##STR2## where R is the side chain.
As used herein, the term "all-D-amino acid peptide" refers to a peptide containing only D-amino acids.
I. ANTI-MICROBIAL AND HEMOLYTIC PEPTIDES
This invention provides peptides having anti-microbial activity. As used herein, the term "anti-microbial activity" means having IC50 less than 30 μgms/ml against a bacteria and IC50 less than 100 μgms/ml against a yeast. More specifically, these peptides have anti-microbial activity against bacteria such as gram-negative bacteria (e.g., E. coli or P. aeruginosa), gram-positive bacteria (e.g., S. aureus or S. sanguis) and against yeast (e.g., C. albicans). Several of these peptides cosine high anti-microbial activity with low hemolytic activity. As used herein, the term "low hemolytic activity" means having HD50 (% hemolysis) greater than 100 μgms/ml. In one embodiment of this invention, peptides have an anti-microbial activity less than 10 μgms/ml against a bacterium or yeast.
This invention also provides peptides that find use due to their high hemolytic activity, without regard to their anti-microbial activity. As used herein, the term "high hemolytic activity" means having HD50 (% hemolysis) less than 100 μgms/ml.
A. (KFmoc)ZZZ-NH
2
This invention provides anti-microbial peptides having the general formulae:
______________________________________SEQUENCE ID NO: PEPTIDE______________________________________1 (KFmoc)ZZZ-NH22 (KFmoc)WZZ-NH23 (KFmoc)WKZ-NH24 (KFmoc)WYZ-NH2-- (KFmoc)WfZ-NH2-- (KFmoc)ciZ-NH2,______________________________________
wherein Z is an amino acid.
In particular, this invention provides anti-microbial peptides having the formula:
______________________________________SEQUENCE ID NO: PEPTIDE______________________________________3 (KFmoc)WKW-NH23 (KFmoc)WKC-NH23 (KFmoc)WKF-NH23 (KFmoc)WKS-NH23 (KFmoc)WKM-NH23 (KFmoc)WKY-NH23 (KFmoc)WKK-NH23 (KFmoc)WKT-NH23 (KFmoc)WKR-NH23 (KFmoc)WKG-NH23 (KFmoc)WKZ-NH23 (KFmoc)WKL-NH23 (KFmoc)WKH-NH23 (KFmoc)WKV-NH23 (KFmoc)WKI-NH23 (KFmoc)WKN-NH23 (KFmoc)WKA-NH23 (KFmoc)WKQ-NH23 (KFmoc)WKP-NH23 (KFmoc)WKD-NH23 (KFmoc)WKE-NH22 (KFmoc)WZZ-NH21 (KFmoc)ZZZ-NH2-- (KFmoc)WKw-NH2-- (KFmoc)WKc-NH2-- (KFmoc)WKl-NH2-- (KFmoc)WKs-NH2-- (KFmoc)WKh-NH2-- (KFmoc)WKy-NH2-- (KFmoc)WKr-NH2-- (KFmoc)WKa-NH2-- (KFmoc)WKq-NH2-- (KFmoc)WKm-NH2-- (KFmoc)WKz-NH2-- (KFmoc)WKp-NH2-- (KFmoc)WKk-NH2-- (KFmoc)WKi-NH2-- (KFmoc)WKv-NH2-- (KFmoc)WKt-NH2-- (KFmoc)WKf-NH2-- (KFmoc)WKn-NH2-- (KFmoc)WKd-NH2-- (KFmoc)WKe-NH23 (KFmoc)WK(NO2 F)-NH23 (KFmoc)WK(Orn)-NH23 (KFmoc)WK(dOrn)-NH23 (KFmoc)WK(aABA)-NH23 (KFmoc)WK(Nle)-NH23 (KFmoc)WKZ-NH23 (KFmoc)WK(KFmoc)-NH23 (KFmoc)WK(aAIB)-NH23 (KFmoc)WK(KCBZ)-NH23 (KFmoc)WK(MetO2)-NH23 (KFmoc)WK(Hyp)-NH23 (KFmoc)WK(Nve)-NH23 (KFmoc)WK(Cys ACM!)-NH23 (KFmoc)WK(Bala)-NH23 (KFmoc)WK(Thiopro)-NH23 (KFmoc)WK(bAsp)-NH23 (KFmoc)WK(7aHa)-NH23 (KFmoc)WK(gGlu)-NH23 (KFmoc)WK(gABA)-NH23 (KFmoc)WK(eAca)-NH24 (KFmoc)WYR-NH24 (KFmoc)WYK-NH24 (KFmoc)WYL-NH24 (KFmoc)WYW-NH24 (KFmoc)WYT-NH24 (KFmoc)WYH-NH24 (KFmoc)WYY-NH24 (KFmoc)WYZ-NH24 (KFmoc)WYP-NH24 (KFmoc)WYV-NH24 (KFmoc)WYG-NH24 (KFmoc)WYA-NH24 (KFmoc)WYN-NH24 (KFmoc)WYS-NH24 (KFmoc)WYQ-NH24 (KFmoc)WYM-NH24 (KFmoc)WYI-NH24 (KFmoc)WYC-NH24 (KFmoc)WYF-NH22 (KFmoc)WZZ-NH21 (KFmoc)ZZZ-NH2-- (KFmoc)WYr-NH2-- (KFmoc)WYs-NH2-- (KFmoc)WYa-NH2-- (KFmoc)WYk-NH2-- (KFmoc)WYp-NH2-- (KFmoc)WYn-NH2-- (KFmoc)WYh-NH2-- (KFmoc)WYl-NH24 (KFmoc)WYZ-NH2-- (KFmoc)WYm-NH2-- (KFmoc)WYv-NH2-- (KFmoc)WYt-NH2-- (KFmoc)WYq-NH2-- (KFmoc)WYi-NH2-- (KFmoc)WYf-NH2-- (KFmoc)WYw-NH2-- (KFmoc)WYc-NH2-- (KFmoc)WYy-NH24 (KFmoc)WY(aABA)-NH24 (KFmoc)WY(7aHa)-NH24 (KFmoc)WY(dOrn)-NH24 (KFmoc)WY(Orn)-NH24 (KFmoc)WYZ-NH24 (KFmoc)WY(KCBZ)-NH24 (KFmoc)WY(Hyp)-NH24 (KFmoc)WY(aAIB)-NH24 (KFmoc)WY(Nle)-NH24 (KFmoc)WY(eAca)-NH24 (KFmoc)WY(NO2 F)-NH24 (KFmoc)WY(Bala)-NH24 (KFmoc)WY(Thiopro)-NH24 (KFmoc)WY(Nve)-NH24 (KFmoc)WY(Cys ACM!)-NH24 (KFmOC)WY(gABA)-NH24 (KFmoc)WY(MetO2)-NH2-- (KFmoc)WfR-NH2-- (KFmoc)WfL-NH2-- (KFmoc)WfP-NH2-- (KFmoc)WfZ-NH2-- (KFmoc)WfK-NH2-- (KFmoc)WfN-NH2-- (KFmoc)WfH-NH2-- (KFmoc)WfT-NH2-- (KFmoc)WfV-NH2-- (KFmoc)WfS-NH2-- (KFmoc)WfA-NH2-- (KFmoc)WfM-NH2-- (KFmoc)WfF-NH2-- (KFmoc)WfC-NH2-- (KFmoc)WfI-NH2-- (KFmoc)WfY-NH22 (KFmoc)WZZ-NH21 (KFmoc)ZZZ-NH2-- (KFmoc)Wfl-NH2-- (KFmoc)Wfw-NH2-- (KFmoc)Wfr-NH2-- (KFmoc)Wfi-NH2-- (KFmoc)WfZ-NH2-- (KFmoc)Wff-NH2-- (KFmoc)Wfm-NH2-- (KFmoc)Wfv-NH2-- (KFmoc)Wfp-NH2-- (KFmoc)Wft-NH2-- (KFmoc)Wfa-NH2-- (KFmoc)Wfs-NH2-- (KFmoc)Wfh-NH2-- (KFmoc)Wfk-NH2-- (KFmoc)Wfq-NH2-- (KFmoc)Wfy-NH2-- (KFmoc)Wfc-NH2-- (KFmoc)Wfn-NH2-- (KFmoc)Wf(KCBZ)-NH2-- (KFmoc)Wf(Thiopro)-NH2-- (KFmoc)Wf(dOrn)-NH2-- (KFmoc)Wf(Orn)-NH2-- (KFmoc)Wf(aAIB)-NH2-- (KFmoc)WfZ-NH2-- (KFmoc)Wf(MetO2)-NH2-- (KFmoc)Wf(Hyp)-NH2-- (KFmoc)Wf(Nve)-NH2-- (KFmoc)Wf(aABA)-NH2-- (KFmoc)Wf(7aHa)-NH2-- (KFmoc)Wf(Nle)-NH2-- (KFmoc)Wf(NO2 F)-NH2-- (KFmoc)Wf(gABA)-NH2-- (KFmoc)Wf(Bala)-NH2-- (KFmoc)Wf(Cys ACM!)-NH2-- (KFmoc)ciR-NH2-- (KFmoc)ciK-NH2-- (KFmoc)ciP-NH2-- (KFmoc)ciM-NH2-- (KFmoc)ciH-NH2-- (KFmoc)ciA-NH2-- (KFmoc)ciW-NH2-- (KFmoc)ciT-NH2-- (KFmoc)ciL-NH2-- (KFmoc)ciZ-NH2-- (KFmoc)ciY-NH2-- (KFmoc)ciS-NH2-- (KFmoc)ciI-NH2-- (KFmoc)ciF-NH2-- (KFmoc)ciN-NH2-- (KFmoc)ciV-NH2-- (KFmoc)cZZ-NH21 (KFmoc)ZZZ-NH2-- (KFmoc)cir-NH2-- (KFmoc)cik-NH2-- (KFmoc)cip-NH2-- (KFmoc)cil-NH2-- (KFmoc)ciZ-NH2-- (KFmoc)cit-NH2-- (KFmoc)ciw-NH2-- (KFmoc)cim-NH2-- (KFmoc)cic-NH2-- (KFmoc)cif-NH2-- (KFmoc)ciy-NH2-- (KFmoc)cis-NH2-- (KFmoc)ci(aAIB)-NH2-- (KFmoc)ci(Orn)-NH2-- (KFmoc)ci(dOrn)-NH2-- (KFmoc)ci(KCBZ)-NH2-- (KFmoc)ci(aABA)-NH2-- (KFmoc)ci(Hyp)-NH2-- (KFmoc)ci(Thiopro)-NH2-- (KFmoc)ciZ-NH2-- (KFmoc)ci(KFmoc)-NH2-- (KFmoc)ci(7aHa)-NH2-- (KFmoc)ci(eAca)-NH2-- (KFmoc)ci(Nve)-NH2-- (KFmoc)ci(Nle)-NH2-- (KFmoc)ci(NO2 F)-NH2______________________________________
In particular, this invention provides anti-microbial peptides having the formula (KFmoc)ZZZ-NH2 SEQ ID NO: 1!, wherein Z is an amico acid said peptide having an IC50 less than 30 μgms/ml and more particularly, HD50 (% hemolysis) greater than 100 μgms/ml.
This invention provides compositions comprising anti-microbial or hemolytic peptides, in particular having the formula (KFmoc)ZZZ-NH2 SEQ ID NO: 1!, wherein Z is an amino acid, in an acceptable carrier. These compositions find use as disinfectants and in methods to retard the growth of microorganisms. They also find use in methods of treating subjects with microbial infections. Compositions comprising hemolytic peptides find use, e.g., in diagnostic procedures requiring lysis of red blood cells.
This invention provides pharmaceutical compositions comprising a peptide having the formula (KFmoc)ZZZ-NH2, wherein Z is an amino acid in a pharmaceutically acceptable carrier, said peptide having anti-microbial activity. In particular, this invention provides pharmaceutical compositions in which the peptide has HD50 greater than 100 μgms/ml.
This invention provides methods of treating a subject infected with a microorganism comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a peptide having the formula (KFmoc)ZZZ-NH2 SEQ ID NO: 1!, wherein Z is an amino acid, said peptide having anti-microbial activity against the said microorganism. In particular, this invention provides methods in which the peptide has HD50 greater than 100 μgms/ml.
This invention provides methods of inhibiting the growth of a microorganism comprising the step of contacting the microorganism with an effective amount of a peptide having the formula (KFmoc)ZZZ-NH2 SEQ ID NO: 1!, wherein Z is an amino acid, said peptide having anti-microbial activity against the microorganism. In particular, this invention provides this method wherein the peptide has HD50 greater than 100 μgms/ml. An effective amount is at least the IC50 concentration.
This invention also provides methods of lysing red blood cells comprising the step of contacting red blood cells with an effective amount of a peptide having the formula (KFmoc)ZZZ-NH2 SEQ ID NO: 1!, wherein Z is an amino acid, and the peptide has HD50 less then 100 μgms/ml. An effective amount is at least the IC50 concentration.
B. Ac-RRWWCZ-NH
2 SEQ ID NO: 6!
This invention provides methods using anti-microbial peptides having the general formulae:
______________________________________SEQUENCE ID NO: PEPTIDE______________________________________5 Ac-RRWWZZ-NH26 Ac-RRWWCZ-NH2,______________________________________
wherein Z is an amino acid.
In particular, this invention provides methods using peptides having the formula:
______________________________________SEQUENCE ID NO: PEPTIDE______________________________________6 Ac-RRWWCA-NH26 Ac-RRWWCC-NH26 Ac-RRWWCD-NH26 Ac-RRWWCE-NH26 Ac-RRWWCF-NH26 Ac-RRWWCG-NH26 Ac-RRWWCH-NH26 Ac-RRWWCI-NH26 Ac-RRWWCK-NH26 Ac-RRWWCL-NH26 Ac-RRWWCM-NH26 Ac-RRWWCN-NH26 Ac-RRWWCP-NH26 Ac-RRWWCQ-NH26 Ac-RRWWCR-NH26 Ac-RRWWCS-NH26 Ac-RRWWCT-NH26 Ac-RRWWCV-NH26 Ac-RRWWCW-NH26 Ac-RRWWCY-NH2______________________________________
This invention also provides pharmaceutical compositions comprising a peptide having the formula Ac-RRWWCZ-NH2 SEQ ID NO: 6!, wherein Z is an amino acid, in a pharmaceutically acceptable carrier, said peptide having an IC50 less than 30 μgms/ml against E. coli, S. aureus, S. sangiunis, C. albicans or P. aeruginosa. In particular, this invention provides pharmaceutical compositions in which the peptide has HD50 greater than 100 μgms/ml.
This invention also provides methods of treating a subject infected with a gram-negative bacterium (e.g. E. coli or P. aeruginosa), or a yeast (e.g. C. albicans) comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a peptide having the formula Ac-RRWWCZ-NH2 SEQ ID NO: 6!, or Ac-rrwwcz-NH2 SEQ ID NO: 6!, wherein z is a D-amino acid, in a pharmaceutically acceptable carrier, said peptide having an IC50 less than 30 μgms/ml against the microorganism. In particular, this invention provides methods in which the peptide has HD50 greater than 100 μgms/ml.
This invention also provides methods of inhibiting the growth of a gram-negative bacterium (e.g. E. coli or P. aeruginosa), or a yeast (e.g., C. albicans) comprising the step of contacting the microorganism with an effective amount of a peptide having the formula Ac-RRWWCZ-NH2, wherein Z is an amino acid, said peptide having an IC50 less than 30 μgms/ml against the microorganism. In particular, this invention provide methods wherein the peptide has HD50 greater than 100 μgms/ml. An effective amount is at least the IC50 concentration.
This invention also provides methods of lysing red blood cells comprising the step of contacting red blood cells with an effective amount of a peptide having the formula Ac-RRWWCZ-NH2, wherein Z is an amino acid, wherein the peptide has HD50 less than 100 μgms/ml. An effective amount is at least the IC50 concentration.
C. Ac-rrwwz-NH
2
This invention also provides anti-microbial peptides having the formula:
______________________________________SEQUENCE ID NO: PEPTIDE______________________________________-- Ac-rrwwz-NH2,______________________________________
wherein Z is an amino acid, and, in particular, wherein z is a D-amino acid; wherein the peptide has anti-microbial activity IC50 less than 30 μgms/ml and more particularly, less than 10 μgms/ml. It also provides these peptides having HD50 greater than 100 μgms/ml.
In particular, this invention provides peptides having the formula:
______________________________________SEQUENCE ID NO: PEPTIDE______________________________________-- Ac-rrwwcr-NH2-- Ac-rrwwcv-NH2______________________________________
This invention provides pharmaceutical compositions comprising a peptide having the formula (KFmoc)ZZZ-NH2, wherein Z is an amino acid in a pharmaceutically acceptable carrier, said peptide having anti-microbial activity. In particular, this invention provides pharmaceutical compositions in which the peptide has HD50 greater than 100 μgms/ml.
This invention provides methods of treating a subject infected with a microorganism comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a peptide having the formula wherein z is a D-amino acid said peptide having anti-microbial activity against the said microorganism. In particular, this invention provides methods in which the peptide has HD50 greater than 100 μgms/ml.
This invention provides methods of inhibiting the growth of a microorganism comprising the step of contacting the microorganism with an effective amount of a peptide having the formula wherein z is a D-amino acid said peptide having anti-microbial activity against the microorganism. In particular, this invention provides this method wherein the peptide has HD50 greater than 100 μgms/ml. An effective amount is at least the IC50 concentration.
This invention also provides methods of lysing red blood cells comprising the step of contacting red blood cells with an effective amount of a peptide having the formula wherein z is a D-amino acid and the peptide has HD50 less than 100 μgms/ml. An effective amount is at least the IC50 concentration.
II. ANTI-MELITTIN PEPTIDES
This invention provides peptides having anti-melittin activity. Melittin is the active compound in bee venom, and causes cell lysis. It has the formula:
______________________________________SEQ ID NO: PEPTIDE______________________________________7 GIGAVLKVLT TGLPALISW IKRKRQQ-NH2______________________________________
One can synthesize melittin by any known method for peptide synthesis.
This invention provides peptides having anti-melittin activity having the general formulae:
______________________________________SEQ ID NO: PEPTIDE______________________________________ 8 Ac-IVILZZ-NH2 9 Ac-IVILTZ-NH210 Ac-IVILLZ-NH211 Ac-IVIFFZ-NH2______________________________________
wherein Z is an amino acid.
In particular, this invention provides peptides having the formula:
______________________________________SEQ ID NO: PEPTIDE______________________________________ 9 Ac-IVILTM-NH2 9 Ac-IVILTF-NH2 9 Ac-IVILTL-NH2 9 Ac-IVILTQ-NH2 9 Ac-IVILTW-NH2 9 Ac-IVILTA-NH2 9 Ac-IVILTN-NH2 9 Ac-IVILTY-NH2 9 Ac-IVILTC-NH2 9 Ac-IVILTV-NH2 9 Ac-IVILTG-NH2 9 Ac-IVILTE-NH2 9 Ac-IVILTS-NH2 9 Ac-IVILTT-NH2 9 Ac-IVILTP-NH2 9 Ac-IVILTH-NH2 9 Ac-IVILTI-NH2 9 Ac-IVILTK-NH2 9 Ac-IVILTR-NH210 Ac-IVILLW-NH210 Ac-IVILLE-NH210 Ac-IVILLQ-NH210 Ac-IVILLY-NH210 Ac-IVILLN-NH210 Ac-IVILLS-NH210 Ac-IVILLA-NH210 Ac-IVILLG-NH210 Ac-IVILLD-NH210 Ac-IVILLT-NH210 Ac-IVILLM-NH210 Ac-IVILLF-NH210 Ac-IVILLP-NH210 Ac-IVILLI-NH210 Ac-IVILLV-NH210 Ac-IVILLL-NH210 Ac-IVILLC-NH210 Ac-IVILLH-NH210 Ac-IVILLK-NH210 Ac-IVILLR-NH211 Ac-IVIFFD-NH211 Ac-IVIFFE-NH211 Ac-IVIFFW-NH211 Ac-IVIFFN-NH211 Ac-IVIFFM-NH211 Ac-IVIFFY-NH211 Ac-IVIFFS-NH211 Ac-IVIFFG-NH211 Ac-IVIFFT-NH211 Ac-IVIFFA-NH211 Ac-IVIFFQ-NH211 Ac-IVIFFV-NH211 Ac-IVIFFH-NH211 Ac-IVIFFP-NH211 Ac-IVIFFC-NH211 Ac-IVIFFI-NH211 Ac-IVIFFL-NH211 Ac-IVIFFF-NH211 Ac-IVIFFK-NH211 Ac-IVIFFR-NH2______________________________________
This invention provides peptides having anti-melittin activity having the formula:
______________________________________SEQ ID NO: PEPTIDE______________________________________12 Ac-Z1 Z2 IZ3 Z4 Z5 -NH2,______________________________________
wherein Z1, Z2, Z3, Z4 and Z5 are amino acids, and in particular wherein Z1 is F or I; Z2 is I, Q or D; Z3 is W or Y; Z4 is C or F and Z5 is E or K.
In particular, this invention is directed to peptides having the formula:
______________________________________SEQ ID NO: PEPTIDE______________________________________12 Ac-FIIWCE-NH212 Ac-IIIWCE-NH212 Ac-FIIYCE-NH212 AC-IQIYCE-NH212 Ac-IIIYFE-NH212 Ac-IIIWFE-NH212 Ac-FIIWFE-NH212 Ac-IQIWCE-NH212 Ac-FIIYFE-NH212 Ac-FQIWFE-NH212 Ac-FQIWCE-NH212 Ac-IIIYCE-NH212 Ac-FQIYCE-NH212 Ac-IQIYFE-NH212 Ac-FQIYFE-NH212 Ac-IQIWFE-NH212 Ac-IDIWCK-NH212 Ac-FDIWFK-NH212 Ac-FDIWFE-NH212 Ac-FDIYCE-NH212 Ac-IDIYCE-NH212 Ac-IDIYFE-NH212 Ac-FIIYFK-NH212 Ac-IDIYFK-NH212 Ac-IDIWCE-NH212 Ac-FDIYFE-NH212 Ac-IQIYCK-NH212 Ac-FIIWFK-NH2______________________________________
This invention also provides peptides having the formula:
______________________________________SEQ ID NO: PEPTIDE______________________________________13 Ac-MILWIE-NH214 Ac-VIQQFV-NH215 AC-WIQIFI-NH2______________________________________
In particular, this invention also provides anti-melittin peptides having IC50 less than 30 μgms/ml.
This invention provides methods of inhibiting melittin activity comprising the step of contacting melittin with an effective amount of a peptide having the formula Ac-IVILTZ-NH2 SEQ ID NO: 9!, Ac-IVILLZ-NH2 SEQ ID NO: 10!, Ac-IVIFFZ-NH2 SEQ ID NO: 11!, having an IC50 less than 30 μgms/ml. An effective amount is at least the IC50 concentration.
This invention also provides compositions comprising a peptide having the formula Ac-IVILTZ-NH2 SEQ ID NO: 9!, Ac-IVILLZ-NH2 SEQ ID NO: 10!, Ac-IVIFFZ-NH2 SEQ ID NO: 11!, or Ac-Z1 Z2 IZ3 Z4 Z5 -NH2, wherein Z is an amino acid, Ac-MILWIE-NH2, Ac-VIQQFV-NH2, Ac-WIQIFI-NH2 in an acceptable carrier.
This invention also provides pharmaceutical compositions comprising a peptide having the formula Ac-IVILTZ-NH2 SEQ ID NO: 6!, Ac-IVILLZ-NH2 SEQ ID NO: 10!, Ac-IVIFFZ-NH2 SEQ ID NO: 11!, or Ac-Z1 Z2 IZ3 Z4 Z5 -NH2 SEQ ID NO: 12!, wherein Z is an L-amino acid, Ac-MILWIE-NH2, Ac-VIQQFV-NH2, Ac-WIQIFI-NH2 in a pharmaceutically acceptable carrier.
This invention also provides methods of treating a subject suffering from melittin poisoning comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a peptide of having the formula Ac-IVILTZ-NH2 SEQ ID NO: 9!, Ac-IVILLZ-NH2 SEQ ID NO: 10!, Ac-IVIFFZ-NH2 SEQ ID NO: 11!, or Ac-Z1 Z2 IZ3 Z4 Z5 SEQ ID NO: 12!, wherein Z is an L-amino acid, said peptide having an HD50 greater than 100 μgms/ml. Melittin poisoning results from introducion of melittin into a subject to cause significant cell lysis, for example by bee sting.
III. ANTI-TRYPSIN PEPTIDES
This invention provides all-D-amino acid anti-trypsin peptides having an IC50 less than 150 μM at a trypsin concentration of 193 nM. These peptides find use in methods of inhibiting trypsin activity. For example, these peptides find use in quenching trypsin activity in assays or procedures calling for limited trypsin digestion.
In particular, this invention provides peptides having the formula:
______________________________________SEQ ID NO: PEPTIDE______________________________________-- Ac-ryrpwz-NH2______________________________________
wherein z is a D-amino acid.
More particularly, this invention provides the peptides:
______________________________________SEQ ID NO: PEPTIDE______________________________________-- Ac-ryrpwp-NH2-- Ac-ryrpww-NH2-- Ac-ryrpwv-NH2-- Ac-ryrpwc-NH2-- Ac-ryrpwt-NH2______________________________________
This invention also provides methods of inhibiting trypsin activity comprising the step of contacting trypsin with an effective amount of a peptide having the formula Ac-ryrpwz-NH2, wherin z is a D-amino acid. An effective amount is at least the IC50 concentration.
One skilled in the art can easily produce any of the individual peptides of this invention by simultaneous multi peptide synthesis (Example I) or by synthesis on an automated peptide synthesizer, according to the manufacturer's instructions (Model 430A, Applied Biosystems, Foster City, Calif. USA).
This invention provides pharmaceutical compositions comprising the peptides of this invention in a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents.
Suitable pharmaceutical carriers and their formulations are described in Martin, REMINGTON'S PHARMACEUTICAL SCIENCES, 15th Ed. (Mack Publishing Co., Easton 1975). Such compositions will, in general, contain an effective amount of the active reagent together with a suitable amount of carrier so as to prepare the proper dosage form for proper administration to the subject.
Useful pharmaceutical carriers for the preparation of the pharmaceutical compositions can be solids, liquids or gases. Thus, the compositions can take the form of tablets, pills, capsules, powders, enterically coated or other protected formulations (such as by binding on ion exchange resins or other carriers, or packaging in lipid protein vesicles or adding additional terminal amino acids), sustained release formulations, solutions (e.g. ophthalmic drops), suspensions, elixirs, aerosols, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly (when isotonic) for injectable solutions. The carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Suitable pharmaceutical excipients include starch, cellulose. talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
The compositions may be subjected to conventional pharmaceutical procedures such as sterilization and may contain conventional pharmaceutical additives such as preservatives, stabilizing agents, wetting or emulsifying agents, salts for adjusting osmotic pressure, buffers, and the like.
This invention provides methods of treating a subject comprising the step of administering a therapeutically effective amount of a pharmaceutical composition of this invention to a subject. As used herein, the term "therapeutically effective amount" is that amount necessary to alleviate the condition from which the subject suffers. As used herein, the term "subject" includes animals, vertebrates, mammals or humans.
In the practice of the therapeutic methods of the present invention, an effective amount of a peptide of this invention, including derivatives or salts thereof, or a pharmaceutical composition containing the same, as described above, is administered via any of the usual and acceptable methods known in the art, either singly or in combination with another peptide or peptides of the present invention or other pharmaceutical agents such as anti-inflammatory agents, or other therapeutics known to have an effect on inflammation or the like. These compounds or compositions can thus be administered orally, sublingually, topically (e.g., on the skin or in the eyes), parenterally (e.g., intramuscularly, intravenously, subcutaneously or intradermally), or by inhalation, and in the form of either solid, liquid or gaseous dosage including tablets, suspensions, and aerosols, as is discussed in more detail above. The administration can be conducted in single unit dosage form with continuous therapy or in single dose therapy ad libitum.
In one embodiment, the therapeutic methods of the present invention are practiced when the relief of symptoms is specifically required or perhaps imminently so. In another embodiment, the method is effectively practiced as continuous or prophylactic treatment.
In the practice of the therapeutic methods of the invention, the particular dosage of pharmaceutical composition to be administered to the subject will depend on a variety of considerations including the nature of the disease, the severity thereof, the schedule of administration, the age and physical characteristics of the subject, and so forth. Proper dosages may be established using clinical approaches familiar to the medicinal arts. It is presently believed that dosages in the range 0.1 of 100 mg of a peptide of this invention per kilogram of subject body weight will be useful, and a range of 1 to 100 mg per kg generally preferred where the administration is by injection or ingestion. Topical dosages may utilize formulations containing active peptides and a liquid carrier or excipient, with multiple daily applications being appropriate.
This invention also provides methods of inhibiting the growth of microorganisms comprising the step of contacting the microorganism with an effective amount of a peptide of this invention. Methods of contacting a microorganism with a peptide of this invention include, for example, those described in Example I, Section B.
This invention provides methods of inhibiting melittin activity comprising the step of contacting melittin with an effective amount of a peptide of this invention. Such methods include, for example, those described in Example II, Section B.
This invention provides methods of inhibiting trypsin activity comprising the step of contacting trypsin with an effective amount of a peptide of this invention. Such methods include, for example, those described in Example III, Section B.
EXAMPLE I
PEPTIDES HAVING ANTI-MICROBIAL ACTIVITY
A. Synthetic Peptide Libraries
A synthetic peptide library was prepared using methylbenzhydrylamine (MBHA) polystyrene resin and standard t-Boc chemistry in combination with simultaneous multiple peptide synthesis (SMPS) (R. A. Houghten, Proc. Natl. Acad. Sci. U.S.A. 82., 5131-5135 (1985); U.S. Pat. No. 4,631,211 (each of which is incorporated herein by reference)). A divide, couple and recombine (DCR) process was used to synthesize the XXXX-peptide resin wherein X is an eguimolarmixture of selected amino acids. This process assures equimolarity of the peptides on the resin.
Briefly, 18 porous polypropylene packets, each containing 4.65 mmol (5.00 g) of MBHA resin, were coupled to each of the protected N-α-t-Boc amino acids of interest. All coupling reactions proceeded to completion (greater than 99.5%), as assessed by Gisin's picric acid (B. F. Gisin, Analytica Chim. Acta. 58, 248-249 (1972)) or Kaiser's ninhydrin tests (E. T. Kaiser, Analyt. Biochem 34, 595-598 (1970)).
The resulting resins from each packet were then combined and thoroughly mixed. This resin mixture was separated into 18 portions of equal weight which were placed into porous polypropylene packets, followed by N-α-t-Boc protecting group removal and neutralization of the resulting amine TFA salts. The resin packets were then reacted with solutions of the individual activated amino acids to yield the 324 dipeptide combinations (182).
The above DCR process was repeated twice more, yielding a final mixture of 104,976 protected tetra-peptide resins (184). This XXXX-resin was divided into 324 aliquots (150 mg each) and placed in numbered, porous polypropylene packets.
Synthesis of the next two defined positions was carried out by SMPS. The peptide mixtures were deprotected and cleaved from their respective resins using low-high hydrogen fluoride (HF) (J. P. Tam et al., J. Am. Chem. Soc. 105, 6442-6455 (1983)) as described for individual peptides earlier (J. H. Cuervo et al., Peptide Res. 1, 81-86 (1988); and R. A. Boughten et al., Int. J. Peptide Protein Res. 27, 673-678 (1986)) in a multiple HF cleavage apparatus (Multiple Peptide Systems, San Diego, Calif.). Extraction of the individual peptide mixtures was carried out with distilled water.
B. Antimicrobial Assays
1. E. coli, P. aeruginosa and S. aureus
Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as Gram-negative (-) and Staphylococcus aureus ATCC 29213 as Gram-positive (+) bacteria. Bacteria were grown overnight at 37° C. in Mueller-Hinton (MH) broth. This culture was reinoculated and incubated at 37° C. to reach the exponential phase of bacteria growth, i.e., a final bacterial suspension containing 105 to 5×105 colony-forming units (CFU)/ml. The concentration of cells was established by plating 100 μl of different dilutions of the culture solution (e.g., 10-2, 10-2 and 10-4) onto solid agar plates.
Following an overnight incubation at 37° C., the CFU thus formed were counted on each agar plate. In 96-well tissue culture plates, as control blanks, eight wells per plate contained only medium, while as a positive growth control, eight other wells contained medium plus cells. These controls were used to detect possible medium contamination and to provide a measure of uninhibited growth of the microorganisms.
For IC50 (concentration necessary to inhibit 50% growth of bacteria), peptides were added to the bacterial suspension at concentrations derived from two-fold dilutions ranging from 1000 μg/ml to 1.95 μg/ml.
The plates were incubated overnight at 37° C., and the optical density (OD) determined at 620 nm after different times of incubation.
2. S. sanguis
Streptococcus sanguis ATCC 10556 (Gram-positive (+) bacteria present in tooth crevices) was grown overnight at 37° C. in Brain Heart Infusion (BHI) broth. This culture was reinoculated and incubated at 37° C. to reach the exponential phase of bacteria growth, i.e., a final bacterial suspension containing 105 to 5×105 colony-forming units (CFU)/ml. The concentration of cells was established by plating 100 μl of different dilutions of the culture solution (e.g., 10-2, 10-3 and 10-4) onto solid agar plates. Following an overnight incubation at 37° C., the CFU thus formed were counted on each agar plate. In 96-well tissue culture plates, as control blanks, eight wells per plate contained only medium, while as a positive growth control, eight other wells contained medium plus cells. These controls were used to detect possible medium contamination and to provide a measure of uninhibited growth of the microorganisms. For IC50 (concentration necessary to inhibit 50% growth of bacteria), peptides are added to the bacterial suspension at concentrations derived from two-fold dilutions ranging from 1000 μg/ml to 1.95 μg/ml. The plates were incubated overnight at 37° C., and the optical density (OD) determined at 620 nm after 20 to 24 hours incubation.
3. C. albicans
The organism used for antifungal studies was Candida albicans ATCC 10231. The yeast culture was spread onto YM agar plates and incubated at 30° C. for 48 hours. Three colonies of this culture (approx. 1 mm in diameter each) were then inoculated in 5 ml of 1X PBS solution. The suspension was vortexed and diluted 10-fold in YM broth, for an approximate final concentration of 105 to 5×105 CFU (colony forming units)/ml. Actual concentration of yeast culture was determined by plating 100 μl of different solutions of the culture solution (10-3, 10-4, 10-5) onto solid YM agar plates.
After 48 hours of incubation at 30° C., CFU formed were counted from each plate. The assays were carried out in 96-well tissue culture plates. Eight wells containing only medium of YM broth served as negative controls while eight wells containing medium and yeast culture served as positive controls. These controls were used to detect possible medium contamination and to provide a measure of uninhibited growth of the yeast. The two antifungal drugs Amphotericin B and Nystatin (both from Sigma Chemical, St. Louis, Mo., U.S.A.) were included in each assay for comparative purpose.
For IC50 (concentration necessary to inhibit 50% growth of the yeast) peptides were added to the yeast suspension at concentrations derived from two-fold dilutions ranging from 1500 μg/ml to 3.13 μg/ml. The plates were incubated over a period of 48 hours at 30° C., and the optical density (OD) at 24 and 48 hours was determined at 620 nm.
C. Hemolytic Activity
Each assay was carried out in 96-well culture tissue plates. Four wells per plate contain 125 μl of a non-peptide positive control (1% Triton in de-ionized water), and four wells per plate contain 125 μl of a control blank, phosphate buffered saline (PBS). The hemolytic peptide melittin was used as comparative control. The controls served to detect possible contamination and to calculate the percent hemolysis of each peptide. Human red blood cells (RBCs) were washed with PBS and centrifuged to separate them from the serum. The cells were then resuspended in PBS to a final suspension of 0.5% RBC. 125 μl of this suspension was added to the peptides and controls solution. The release of hemoglobin resulting from the cell lysis was determined by measuring the OD at 414 nm of 100 μl of the supernatant.
The hemolytic doses, i.e., the concentration necessary to lyse 50% of the cells (HD50), were determined by performing a serial two-fold dilution of the peptide mixture solutions ranging from 1500 μg/ml to 3.13 μg/ml.
D. Results
Tables 2-23 present data on the anti-microbial and hemolytic activities of various peptides. In Tables 2-21 "X" represents and equimolar mixture of the amino acids of Table I, excluding D- and L- cysteine and D- and L- tryptophan.
TABLE 2______________________________________ANTIMICROBIAL ACTIVITY AGAINST E. COLI OF(KFmoc)WKZ-NH2 IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WKW-NH2 14 (KFmoc)WKw-NH2 15(KFmoc)WKL-NH2 18 (KFmoc)WKl-NH2 20(KFmoc)WKF-NH2 20 (KFmoc)WKc-NH2 23(KFmoc)WKM-NH2 26 (KFmoc)WKi-NH2 23(KFmoc)WKY-NH2 27 (KFmoc)WKf-NH2 38(KFmoc)WKC-NH2 28 (KFmoc)WKy-NH2 39(KFmoc)WKI-NH2 29 (KFmoc)WKp-NH2 39(KFmoc)WKV-NH2 32 (KFmoc)WKm-NH2 41(KFmoc)WKX-NH2 41 (KFmoc)WKX-NH2 41(KFmoc)WKT-NH2 42 (KFmoc)WKn-NH2 47(KFmoc)WKS-NH2 46 (KFmoc)WKh-NH2 52(KFmoc)WKA-NH2 5o (KFmoc)WKv-NH2 54(KFmoc)WKG-NH2 66 (KFmoc)WKt-NH2 55(KFmoc)WKP-NH2 67 (KFmoc)WKs-NH2 57(KFmoc)WKR-NH2 74 (KFmoc)WKq-NH2 57(KFmoc)WKQ-NH2 75 (KFmoc)WKa-NH2 60 (KFmoc)WKr-NH2 66(KFmoc)WXX-NH2 32(KFmoc)ZXX-NH2 179(KFmoc)WK(NO2 F)-NH2 18(KFmoc)WK(Nle)-NH2 26(KFmoc)WK(Nve)-NH2 32(KFmoc)WKX-NH2 41(KFmoc)WK(MetO2)-NH2 46(KFmoc)WK(aABA)-NH2 48(KFmoc)WK(Cys ACM!)-NH2 49(KFmoc)WK(Bala)-NH2 51(KFmoc)WK(aAIB)-NH2 57(KFmoc)WK(Hyp)-NH2 62(KFmoc)WK(Thiopro)-NH2 64(KFmoc)WK(gABA)-NH2 65(KFmoc)WK(dOrn)-NH2 69(KFmoc)WK(Orn)-NH2 100(KFmoc)WK(7aHa)-NH2 104______________________________________
TABLE 3______________________________________ANTIMICROBIAL ACTIVITY AGAINST E. COLI OF(KFmoc)WYZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WYR-NH2 23 (KFmoc)WYr-NH2 16(KFmoc)WYK-NH2 35 (KFmoc)WYk-NH2 18(KFmoc)WYH-NH2 35 (KFmoc)WYh-NH2 40(KFmoc)WYX-NH2 42 (KFmoc)WYX-NH2 42(KFmoc)WYP-NH2 66 (KFmoc)WYt-NH2 81(KFmoc)WYT-NH2 71 (KFmoc)WYp-NH2 84(KFmoc)WYG-NH2 72 (KFmoc)WYa-NH2 87(KFmoc)WYS-NH2 94 (KFmoc)WYv-NH2 102 (KFmoc)WYs-NH2 106 (KFmoc)WYf-NH2 116 (KFmoc)WYl-NH2 123(KFmoc)WXX-NH2 32(KFmoc)XXX-NH2 179______________________________________ IC50 (μg/m)______________________________________(KFmoc)WY(Orn)-NH2 29(KFmoc)WY(dOrn)-NH2 35(KFmoc)WYX-NH2 42(KFmoc)WY(aABA)-NH2 43(KFmoc)WY(KCBZ)-NH2 59(KFmoc)WY(aAIB)-NH2 92______________________________________
TABLE 4______________________________________ANTIMICROBIAL ACTIVITY AGAINST E. COLI OF(KFmoc)WfZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WfL-NH2 10 (KFmoc)Wfr-NH2 15(KFmoc)WfP-NH2 17 (KFmoc)WfX-NH2 20(KFmoc)WfR-NH2 19 (KFmoc)Wff-NH2 21(KFmoc)WfX-NH2 20 (KFmoc)Wfw-NH2 27(KFmoc)WfK-NH2 76 (KFmoc)Wfl-NH2 28(KFmoc)WfH-NH2 85 (KFmoc)Wfp-NH2 30 (KFmoc)Wfm-NH2 35 (KFmoc)Wft-NH2 51 (KFmoc)Wfv-NH2 73 (KFmoc)Wfh-NH2 73 (KFmoc)Wfq-NH2 76 (KFmoc)Wfc-NH2 86 (KFmoc)Wfk-NH2 101(KFmoc)WXX-NH2 32(KFmoc)XXX-NH2 179______________________________________ IC50 (μg/m)______________________________________(KFmoc)Wf(Thiopro)-NH2 16(KFmoc)Wf(dOrn)-NH2 19(KFmoc)WfX-NH2 20(KFmoc)Wf(aABA)-NH2 21(KFmoc)Wf(Nve)-NH2 22(KFmoc)Wf(aAIB)-NH2 27(KFmoc)Wf(KCBZ)-NH2 28(KFmoc)Wf(Orn)-NH2 30(KFmoc)Wf(Hyp)-NH2 44(KFmoc)Wf(Nle)-NH2 46(KFmoc)Wf(MetO2)-NH2 62(KFmoc)Wf(gABA)-NH2 65(KFmoc)Wf(Bala)-NH2 70(KFmoc)Wf(NO2 F)-NH2 88______________________________________
TABLE 5______________________________________ANTIMICROBIAL ACTIVITY AGAINST E. COLI OF (KFmoc)ciZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)ciT-NH2 17 (KFmoc)cir-NH2 18(KFmoc)ciR-NH2 22 (KFmoc)ciX-NH2 26(KFmoc)ciL-NH2 24 (KFmoc)cik-NH2 27(KFmoc)ciX-NH2 26 (KFmoc)cip-NH2 31(KFmoc)ciP-NH2 28 (KFmoc)cit-NH2 56(KFmoc)ciH-NH2 33 (KFmoc)ciw-NH2 61(KFmoc)ciK-NH2 35 (KFmoc)cic-NH2 61(KFmoc)ciW-NH2 42(KFmoc)ciI-NH2 45(KFmoc)ciF-NH2 47(KFmoc)ciA-NH2 50(KFmoc)ciV-NH2 62(KFmoc)ciM-NH2 75(KFmoc)cZZ-NH2 58(KFmoc)ZZZ-NH2 179______________________________________ IC50 (μg/m)______________________________________(KFmoc)ci(KCBZ)-NH2 15(KFmoc)ci(dOrn)-NH2 20(KFmoc)ci(aAIB)-NH2 22(KFmoc)ci(Thiopro)-NH2 25(KFmoc)ci(aABA)-NH2 25(KFmoc)cix-NH2 26(KFmoc)ci(Orn)-NH2 31(KFmoc)ci(Nve)-NH2 51(KFmoc)ci(Hyp)-NH2 52(KFmoc)ci(Nle)-NH2 78(KFmoc)ci(KFmoc)-NH2 97______________________________________
TABLE 6______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. AUREUS OF(KFmoc)WKZ-NH2 IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WKW-NH2 4 (KFmoc)WKw-NH2 4(KFmoc)WKC-NH2 4 (KFmoc)WKc-NH2 4(KFmoc)WKF-NH2 5 (KFmoc)WKl-NH2 5(KFmoc)WKS-NH2 5 (KFmoc)WKs-NH2 6(KFmoc)WKM-NH2 5 (KFmoc)WKh-NH2 6(KFmoc)WKY-NH2 5 (KFmoc)WKy-NH2 7(KFmoc)WKK-NH2 5 (KFmoc)WKr-NH2 7(KFmoc)WKT-NH2 7 (KFmoc)WKa-NH2 7(KFmoc)WKR-NH2 7 (KFmoc)WKq-NH2 7(KFmoc)WKG-NH2 7 (KFmoc)WKm-NH2 7(KFmoc)WKX-NH2 7 (KFmoc)WKX-NH2 7(KFmoc)WKL-NH2 8 (KFmoc)WKp-NH2 8(KFmoc)WKH-NH2 8 (KFmoc)WKk-NH2 8(KFmoc)WKV-NH2 8 (KFmoc)WKi-NH2 9(KFmoc)WKI-NH2 9 (KFmoc)WKv-NH2 9(KFmoc)WKN-NH2 9 (KFmoc)WKt-NH2 10(KFmoc)WKA-NH2 9 (KFmoc)WKf-NH2 10(KFmoc)WKQ-NH2 10 (KFmoc)WKn-NH2 10(KFmoc)WKP-NH2 13 (KFmoc)WKd-NH2 14(KFmoc)WKD-NH2 25 (KFmoc)WKe-NH2 43(KFmoc)WKE-NH2 37(KFmoc)WXX-NH2 18(KFmoc)XXX-NH2 44(KFmoc)WK(NO2 F)-NH2 5(KFmoc)WK(Orn)-NH2 5(KFmoc)WK(dOrn)-NH2 5(KFmoc)WK(aABA)-NH2 6(KFmoc)WK(Nle)-NH2 7(KFmoc)WKX-NH2 7(KFmoc)WK(KFmoc)-NH2 9(KFmoc)WK(aAIB)-NH2 9(KFmoc)WK(KCBZ)-NH2 9(KFmoc)WK(MetO2)-NH2 9(KFmoc)WK(Hyp)-NH2 10(KFmoc)WK(Nve)-NH2 10(KFmoc)WK(Cys ACM!)-NH2 11(KFmoc)WK(Bala)-NH2 11(KFmoc)WK(Thiopro)-NH2 12(KFmoc)WK(bASp)-NH2 15(KFmoc)WK(7aHa)-NH2 17(KFmoc)WK(gGlu)-NH2 18(KFmoc)WK(gABA)-NH2 18(KFmoc)WK(eAca)-NH2 40______________________________________
TABLE 7______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. AUREUS OF(KFmoc)WYU-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WYR-NH2 5 (KFmoc)WYr-NH2 4(KFmoc)WYK-NH2 6 (KFmoc)WYs-NH2 5(KFmoc)WYL-NH2 7 (KFmoc)WYa-NH2 5(KFmoc)WYW-NH2 7 (KFmoc)WYk-NH2 5(KFmoc)WYT-NH2 8 (KFmoc)WYp-NH2 5(KFmoc)WYH-NH2 8 (KFmoc)WYn-NH2 6(KFmoc)WYY-NH2 8 (KFmoc)WYh-NH2 7(KFmoc)WYX-NH2 8 (KFmoc)WYl-NH2 8(KFmoc)WYP-NH2 9 (KFmoc)WYX-NH2 8(KFmoc)WYV-NH2 9 (KFmoc)WYm-NH2 9(KFmoc)WYG-NH2 9 (KFmoc)WYv-NH2 9(KFmoc)WYA-NH2 10 (KFmoc)WYt-NH2 9(KFmoc)WYN-NH2 11 (KFmoc)WYq-NH2 10(KFmoc)WYS-NH2 11 (KFmoc)WYi-NH2 12(KFmoc)WYQ-NH2 12 (KFmoc)WYf-NH2 12(KFmoc)WYM-NH2 12 (KFmoc)WYw-NH2 16(KFmoc)WYI-NH2 15 (KFmoc)WYc-NH2 21(KFmoc)WYC-NH2 15 (KFmoc)WYy-NH2 26(KFmoc)WYF-NH2 17(KFmoc)WXX-NH2 18(KFmoc)XXX-NH2 44______________________________________ IC50 (μg/m)______________________________________(KFmoc)WY(aABA)-NH2 4(KFmoc)WY(7aHa)-NH2 5(KFmoc)WY(dOrn)-NH2 5(KFmoc)WY(Orn)-NH2 6(KFmoc)WYX-NH2 8(KFmoc)WY(KCBZ)-NH2 9(KFmoc)WY(Hyp)-NH2 9(KFmoc)WY(aAIB)-NH2 10(KFmoc)WY(Nle)-NH2 14(KFmoc)WY(eAca)-NH2 15(KFmoc)WY(NO2 F)-NH2 15(KFmoc)WY(Bala)-NH2 18(KFmoc)WY(Thiopro)-NH2 20(KFmoc)WY(Nve)-NH2 20(KFmoc)WY(Cys ACM!)-NH2 23(KFmoc)WY(gABA)-NH2 35(KFmoc)WY(MetO2)-NH2 40______________________________________
TABLE 8______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. AUREUS OF(KFmoc)WfZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WfR-NH2 2 (KFmoc)Wfl-NH2 2(KFmoc)WfL-NH2 4 (KFmoc)Wfw-NH2 2(KFmoc)WfP-NH2 4 (KFmoc)Wfr-NH2 2(KFmoc)WfX-NH2 4 (KFmoc)Wfi-NH2 4(KFmoc)WfK-NH2 6 (KFmoc)WfX-NH2 4(KFmoc)WfN-NH2 8 (KFmoc)Wff-NH2 5(KFmoc)WfH-NH2 9 (KFmoc)Wfm-NH2 5(KFmoc)WfT-NH2 9 (KFmoc)Wfv-NH2 6(KFmoc)WfV-NH2 13 (KFmoc)Wfp-NH2 7(KFmoc)WfS-NH2 13 (KFmoc)Wft-NH2 7(KFmoc)WfA-NH2 15 (KFmoc)Wfa-NH2 8(KFmoc)WfM-NH2 18 (KFmoc)Wfs-NH2 9(KFmoc)WfF-NH2 21 (KFmoc)Wfh-NH2 9(KFmoc)WfC-NH2 22 (KFmoc)Wfk-NH2 9(KFmoc)WfI-NH2 26 (KFmoc)Wfq-NH2 10(KFmoc)WfY-NH2 58 (KFmoc)Wfy-NH2 15 (KFmoc)Wfc-NH2 18 (KFmoc)Wfn-NH2 35(KFmoc)WXX-NH2 18(KFmoc)XXX-NH2 44______________________________________ IC50 (μg/m)______________________________________(KFmoc)Wf(KCBZ)-NH2 3(KFmoc)Wf(Thiopro)-NH2 3(KFmoc)Wf(dOrn)-NH2 4(KFmoc)Wf(Orn)-NH2 4(KFmoc)Wf(aAIB)-NH2 4(KFmoc)WfX-NH2 4(KFmoc)Wf(MetO2)-NH2 5(KFmoc)Wf(Hyp)-NH2 5(KFmoc)Wf(Nve)-NH2 6(KFmoc)Wf(aABA)-NH2 6(KFmoc)Wf(7aHa)-NH2 7(KFmoc)Wf(Nle)-NH2 9(KFmoc)Wf(NO2 F)-NH2 10(KFmoc)Wf(gABA)-NH2 11(KFmoc)Wf(Bala)-NH2 11(KFmoc)Wf(Cys ACM!)-NH2 18______________________________________
TABLE 9______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. AUREUS OF(KFmoc)ciZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)ciR-NH2 4 (KFmoc)cir-NH2 3(KFmoc)ciK-NH2 4 (KFmoc)cik-NH2 6(KFmoc)ciP-NH2 5 (KFmoc)cip-NH2 8(KFmoc)ciM-NH2 9 (KFmoc)cil-NH2 9(KFmoc)ciH-NH2 9 (KFmoc)ciX-NH2 10(KFmoc)ciA-NH2 9 (KFmoc)cit-NH2 14(KFmoc)ciW-NH2 10 (KFmoc)ciw-NH2 14(KFmoc)ciT-NH2 10 (KFmoc)cim-NH2 17(KFmoc)ciL-NH2 10 (KFmoc)cic-NH2 17(KFmoc)ciX-NH2 10 (KFmoc)cif-NH2 21(KFmoc)ciY-NH2 13 (KFmoc)ciy-NH2 28(KFmoc)ciS-NH2 16 (KFmoc)cis-NH2 29(KFmoc)cil-NH2 19(KFmoc)ciF-NH2 20(KFmoc)ciN-NH2 22(KFmoc)ciV-NH2 23(KFmoc)cXX-NH2 23(KFmoc)XXX-NH2 44______________________________________ IC50 (μg/ml)______________________________________(KFmoc)ci(aAIB)-NH2 4(KFmoc)ci(Orn)-NH2 4(KFmoc)ci(dOrn)-NH2 4(KFmoc)ci(KCBZ)-NH2 5(KFmoc)ci(aABA)-NH2 5(KFmoc)ci(Hyp)-NH2 8(KFmoc)ci(Thiopro)-NH2 9(KFmoc)ciX-NH2 10(KFmoc)ci(KFmoc)-NH2 13(KFmoc)ci(7aHa)-NH2 15(KFmoc)ci(eAca)-NH2 16(KFmoc)ci(Nve)-NH2 16(KFmoc)ci(Nle)-NH2 22(KFmoc)ci(NO2 F)-NH2 25______________________________________
TABLE 10______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. SANGUIS OF(KFmoc)WKZ-NH2 IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WKW-NH2 3 (KFmoc)WKc-NH2 4(KFmoc)WKC-NH2 4 (KFmoc)WKw-NH2 4(KFmoc)WKY-NH2 5 (KFmoc)WKr-NH2 5(KFmoc)WKS-NH2 5 (KFmoc)WKp-NH2 5(KFmoc)WKL-NH2 5 (KFmoc)WKl-NH2 5(KFmoc)WKM-NH2 5 (KFmoc)WKh-NH2 6(KFmoc)WKK-NH2 5 (KFmoc)WKs-NH2 6(KFmoc)WKT-NH2 5 (KFmoc)WKf-NH2 6(KFmoc)WKF-NH2 6 (KFmoc)WKq-NH2 7(KFmoc)WKG-NH2 6 (KFmoc)WKk-NH2 7(KFmoc)WKH-NH2 6 (KFmoc)WKt-NH2 7(KFmoc)WKR-NH2 7 (KFmoc)WKm-NH2 7(KFmoc)WKA-NH2 8 (KFmoc)WKy-NH2 8(KFmoc)WKN-NH2 8 (KFmoc)WKi-NH2 8(KFmoc)WKQ-NH2 9 (KFmoc)WKa-NH2 8(KFmoc)WKP-NH2 9 (KFmoc)WKn-NH2 8(KFmoc)WKI-NH2 9 (KFmoc)WKX-NH2 9(KFmoc)WKV-NH2 9 (KFmoc)WKv-NH2 10(KFmoc)WKX-NH2 9 (KFmoc)WKd-NH2 19(KFmoc)WKD-NH2 31 (KFmoc)WKe-NH2 50(KFmoc)WXX-NH2 10(KFmoc)XXX-NH2 44(KFmoc)WK(Orn)-NH2 5(KFmoc)WK(dOrn)-NH2 5(KFmoc)WK(NO2 F)-NH2 5(KFmoc)WK(Nle)-NH2 6(KFmoc)WK(aABA)-NH2 7(KFmoc)WK(aAIB)-NH2 8(KFmoc)WK(MetO2)-NH2 9(KFmoc)WK(KCBZ)-NH2 9(KFmoc)WK(Nve)-NH2 9(KFmoc)WK(Bala)-NH2 9(KFmoc)WKX-NH2 9(KFmoc)WK(Hyp)-NH2 10(KFmoc)WK(Thiopro)-NH2 11(KFmoc)WK(Cys ACM!)-NH2 11(KFmoc)WK(KFmoc)-NH2 12(KFmoc)WK(gABA)-NH2 14(KFmoc)WK(7aHa)-NH2 19(KFmoc)WK(bAsp)-NH2 19(KFmoc)WK(eAca)-NH2 31(KFmoc)WK(gGlu)-NH2 32______________________________________
TABLE 11______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. SANGUIS OF(KFmoc)WYZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WYR-NH2 5 (KFmoc)WYr-NH2 4(KFmoc)WYK-NH2 6 (KFmoc)WYa-NH2 5(KFmoc)WYT-NH2 8 (KFmoc)WYp-NH2 5(KFmoc)WYL-NH2 8 (KFmoc)WYk-NH2 5(KFmoc)WYH-NH2 9 (KFmoc)WYs-NH2 5(KFmoc)WYP-NH2 9 (KFmoc)WYv-NH2 7(KFmoc)WYS-NH2 9 (KFmoc)WYl-NH2 8(KFmoc)WYW-NH2 9 (KFmoc)WYh-NH2 8(KFmoc)WYG-NH2 9 (KFmoc)WYm-NH2 8(KFmoc)WYY-NH2 10 (KFmoc)WYt-NH2 8(KFmoc)WYV-NH2 10 (KFmoc)WYn-NH2 8(KFmoc)WYM-NH2 11 (KFmoc)WYq-NH2 11(KFmoc)WYN-NH2 12 (KFmoc)WYi-NH2 12(KFmoc)WYA-NH2 12 (KFmoc)WYX-NH2 12(KFmoc)WYX-NH2 12 (KFmoc)WYf-NH2 13(KFmoc)WYQ-NH2 13 (KFmoc)WYw-NH2 21(KFmoc)WYC-NH2 20 (KFmoc)WYy-NH2 32(KFmoc)WYF-NH2 21 (KFmoc)WYc-NH2 42(KFmoc)WYI-NH2 53(KFmoc)WXX-NH2 10(KFmoc)XXX-NH2 44______________________________________ IC50 (μg/m)______________________________________(KFmoc)WY(aABA)-NH2 5(KFmoc)WY(Orn)-NH2 7(KFmoc)WY(dOrn)-NH2 7(KFmoc)WY(aAIB)-NH2 8(KFmoc)WY(KCBZ)-NH2 9(KFmoc)WY(Hyp)-NH2 10(KFmoc)WYX-NH2 12(KFmoc)WY(7aHa)-NH2 14(KFmoc)WY(eAca)-NH2 15(KFmoc)WY(Nle)-NH2 17(KFmoc)WY(Nve)-NH2 18(KFmoc)WY(NO2 F)-NH2 24(KFmoc)WY(Bala)-NH2 26(KFmoc)WY(gABA)-NH2 27(KFmoc)WY(Cys ACM!)-NH2 28(KFmoc)WY(Thiopro)-NH2 36______________________________________
TABLE 12______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. SANGUIS OF(KFmoc)WfZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WfR-NH2 2 (KFmoc)Wfl-NH2 2(KFmoc)WfL-NH2 4 (KFmoc)Wfw-NH2 2(KFmoc)WfP-NH2 4 (KFmoc)Wfr-NH2 2(KFmoc)WfK-NH2 5 (KFmoc)Wfi-NH2 4(KFmoc)WfX-NH2 6 (KFmoc)Wff-NH2 5(KFmoc)WfH-NH2 8 (KFmoc)Wfp-NH2 6(KFmoc)WfA-NH2 10 (KFmoc)WfX-NH2 6(KTmoc)WfN-NH2 10 (KFmoc)Wfv-NH2 7(KFmoc)WfI-NH2 15 (KFmoc)Wft-NH2 7(KFmoc)WfV-NH2 16 (KFmoc)Wfs-NH2 8(KFmoc)WfM-NH2 19 (KFmoc)Wfk-NH2 9(KFmoc)WfF-NH2 20 (KFmoc)Wfm-NH2 9(KFmoc)WfS-NH2 21 (KFmoc)Wfa-NH2 9(KFmoc)WfT-NH2 24 (KFmoc)Wfh-NH2 9(KFmoc)WfC-NH2 31 (KFmoc)Wfq-NH2 15(KFmoc)WfY-NH2 36 (KFmoc)Wfy-NH2 17 (KFmoc)Wfc-NH2 20(KFmoc)WXX-NH2 10(KFmoc)XXX-NH2 44______________________________________ IC50 (μg/m)______________________________________(KFmoc)Wf(Thiopro)-NH2 3(KFmoc)Wf(Orn)-NH2 4(KFmoc)Wf(KCBZ)-NH2 4(KFmoc)Wf(aAIB)-NH2 4(KFmoc)Wf(dOrn)-NH2 4(KFmoc)Wf(Nve)-NH2 5(KFmoc)WfX-NH2 6(KFmoc)Wf(aABA)-NH2 7(KFmoc)Wf(MetO2)-NH2 8(KFmoc)Wf(Hyp)-NH2 8(KFmoc)Wf(gABA)-NH2 9(KFmoc)Wf(Bala)-NH2 10(KFmoc)Wf(7aHa)-NH2 10(KFmoc)Wf(NO2 F)-NH2 11(KFmoc)Wf(Nle)-NH2 12(KFmoc)Wf(Cys ACM!)-NH2 30(KFmoc)Wf(eAca)-NH2 60______________________________________
TABLE 13______________________________________ANTIMICROBIAL ACTIVITY AGAINST S. SANGUIS OF(KFmoc)ciZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)ciR-NH2 3 (KFmoc)cir-NH2 2(KFmoc)ciP-NH2 4 (KFmoc)cik-NH2 4(KFmoc)ciK-NH2 4 (KFmoc)cip-NH2 8(KFmoc)ciH-NH2 5 (KFmoc)ciX-NH2 14(KFmoc)ciM-NH2 10 (KFmoc)ciw-NH2 19(KFmoc)ciW-NH2 12 (KFmoc)cis-NH2 22(KFmoc)ciX-NH2 14 (KFmoc)cit-NH2 27(KFmoc)ciT-NH2 15 (KFmoc)cim-NH2 28(KFmoc)ciL-NH2 16 (KFmoc)cil-NH2 32(KFmoc)ciA-NH2 16 (KFmoc)ciy-NH2 43(KFmoc)ciY-NH2 16 (KFmoc)cih-NH2 50(KFmoc)ciF-NH2 16 (KFmoc)cic-NH2 53(KFmoc)ciS-NH2 22 (KFmoc)cia-NH2 59(KFmoc)ciG-NH2 23 (KFmoc)ciV-NH2 37(KFmoc)ciI-NH2 38(KFmoc)ciN-NH2 47(KFmoc)cXX-NH2 13(KFmoc)XXX-NH2 44______________________________________ IC50 (μg/m)______________________________________(KFmoc)ci(Orn)-NH2 2(KFmoc)ci(dOrn)-NH2 2(KFmoc)ci(KCBZ)-NH2 3(KFmoc)ci(aABA)-NH2 4(KFmoc)ci(aAIB)-NH2 5(KFmoc)ci(Thiopro)-NH2 6(KFmoc)ci(Hyp)-NH2 8(KFmoc)ciX-NH2 14(KFmoc)ci(KFmoc)-NH2 15(KFmoc)ci(Nve)-NH2 19(KFmoc)ci(Nle)-NH2 28(KFmoc)ci(NO2 F)-NH2 36(KFmoc)ci(eAca)-NH2 42(KFmoc)ci(7aHa)-NH2 53______________________________________
TABLE 14______________________________________ANTIFUNGAL ACTIVITY AGAINST C. ALBICANS OF(KFmoc)WKZ-NH2 IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WKF-NH2 65 (KFmoc)WKr-NH2 98(KFmoc)WKI-NH2 79 (KFmoc)WKw-NH2 116(KFmoc)WKL-NH2 97 (KFmoc)WKl-NH2 121(KFmoc)WKR-NH2 108 (KFmoc)WKk-NH2 126(KFmoc)WKW-NH2 124 (KFmoc)WKf-NH2 133(KFmoc)WKY-NH2 138 (KFmoc)WKy-NH2 144(KFmoc)WKV-NH2 148 (KFmoc)WKh-NH2 156(KFmoc)WKX-NH2 163 (KFmoc)WKm-NH2 163(KFmoc)WKK-NH2 191 (KFmoc)WKX-NH2 163(KFmoc)WKM-NH2 213 (KFmoc)WKv-NH2 187(KFmoc)WKG-NH2 217 (KFmoc)WKa-NH2 200(KFmoc)WKS-NH2 218 (KFmoc)WKi-NH2 209(KFmoc)WKH-NH2 221 (KFmoc)WKs-NH2 214(KFmoc)WKT-NH2 260 (KFmoc)WKn-NH2 233(KFmoc)WKC-NH2 269 (KFmoc)WKc-NH2 243(KFmoc)WKQ-NH2 292 (KFmoc)WKp-NH2 251(KFmoc)WKN-NH2 323 (KFmoc)WKq-NH2 291(KFmoc)WKA-NH2 333 (KFmoc)WKt-NH2 292(KFmoc)WKP-NH2 338(KFmoc)WXX-NH2 246(KFmoc)XXX-NH2 770(KFmoc)WK(Nle)-NH2 74(KFmoc)WK(NO2 F)-NH2 101(KFmoc)WK(Nve)-NH2 158(KFmoc)WK(KCBZ)-NH2 161(KFmoc)WKX-NH2 163(KFmoc)WK(Orn)-NH2 177(KFmoc)WK(dOrn)-NH2 196(KFmoc)WK(KFmoc)-NH2 199(KFmoc)WK(Thiopro)-NH2 223(KFmoc)WK(Bala)-NH2 238(KFmoc)WK(aABA)-NH2 245(KFmoc)WK(7aHa)-NH2 252(KFmoc)WK(aAIB)-NH2 281(KFmoc)WK(gABA)-NH2 281(KFmoc)WK(MetO2)-NH2 294(KFmoc)WK(Cys ACM!)-NH2 303(KFmoc)WK(eAca)-NH2 328(KFmoc)WK(Hyp)-NH2 370______________________________________
TABLE 15______________________________________ANTIFUNGAL ACTIVITY AGAINST C. ALBICANS OF(KFmoc)WYZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WYK-NH2 101 (KFmoc)WYr-NH2 109(KFmoc)WYA-NH2 120 (KFmoc)WYk-NH2 121(KFmoc)WYR-NH2 124 (KFmoc)WYt-NH2 161(KFmoc)WYT-NH2 152 (KFmoc)WYp-NH2 165(KFmoc)WYC-NH2 159 (KFmoc)WYh-NH2 192(KFmoc)WYH-NH2 165 (KFmoc)WYX-NH2 227(KFmoc)WYX-NH2 227 (KFmoc)WYa-NH2 249(KFmoc)WYP-NH2 255 (KFmoc)WYs-NH2 353(KFmoc)WYG-NH2 282 (KFmoc)WYv-NH2 467 (KFmoc)WYg-NH2 541(KFmoc)WXX-NH2 246(KFmoc)XXX-NH2 770______________________________________ IC50 (μg/m)______________________________________(KFmoc)WY(Orn)-NH2 183(KFmoc)WY(aABA)-NH2 204(KFmoc)WYX-NH2 227(KFmoc)WY(KCBZ)-NH2 309(KFmoc)WY(dOrn)-NH2 359______________________________________
TABLE 16______________________________________ANTIFUNGAL ACTIVITY AGAINST C. ALBICANS OF(KFmoc)WfZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)WfR-NH2 101 (KFmoc)Wfr-NH2 42(KFmoc)WfP-NH2 133 (KFmoc)Wfl-NH2 127(KFmoc)WfX-NH2 157 (KFmoc)Wfw-NH2 143(KFmoc)WfH-NH2 207 (KFmoc)WfX-NH2 157(KFmoc)WfK-NH2 207 (KFmoc)Wfk-NH2 196(KFmoc)WfL-NH2 267 (KFmoc)Wfh-NH2 338 (KFmoc)Wfp-NH2 347(KFmoc)WXX-NH2 246(KFmoc)XXX-NH2 770______________________________________ IC50 (μg/m)______________________________________(KFmoc)Wf(dOrn)-NH2 54(KFmoc)Wf(KCBZ)-NH2 58(KFmoc)Wf(aAIB)-NH2 62(KFmoc)Wf(aABA)-NH2 72(KFmoc)Wf(Orn)-NH2 89(KFmoc)Wf(Hyp)-NH2 95(KFmoc)Wf(Nve)-NH2 118(KFmoc)Wf(MetO2)-NH2 150(KFmoc)WfX-NH2 157(KFmoc)Wf(Bala)-NH2 170(KFmoc)Wf(Thiopro)-NH2 171(KFmoc)Wf(Nle)-NH2 400______________________________________
TABLE 17______________________________________ANTIFUNGAL ACTIVITY AGAINST C. ALBICANS OF(KFmoc)ciZ-NH2______________________________________ IC50 IC50 (μg/ml) (μg/ml)______________________________________(KFmoc)ciF-NH2 90 (KFmoc)cir-NH2 114(KFmoc)ciL-NH2 122 (KFmoc)cik-NH2 115(KFmoc)ciK-NH2 161 (KFmoc)cit-NH2 194(KFmoc)ciR-NH2 176 (KFmoc)cih-NH2 208(KFmoc)ciH-NH2 201 (KFmoc)cil-NH2 216(KFmoc)ciT-NH2 228 (KFmoc)cif-NH2 218(KFmoc)ciI-NH2 305 (KFmoc)cii-NH2 234(KFmoc)ciP-NH2 216 (KFmoc)cip-NH2 270(KFmoc)ciW-NH2 334 (KFmoc)ciX-NH2 412(KFmoc)ciG-NH2 372(KFmoc)ciX-NH2 412(KFmoc)ciV-NH2 413(KFmoc)ciC-NH2 537(KFmoc)cXX-NH2 343(KFmoc)XXX-NH2 770______________________________________ IC50 (μg/m)______________________________________(KFmoc)ci(KCBZ)-NH2 78(KFmoc)ci(Nve)-NH2 78(KFmoc)ci(Orn)-NH2 115(KFmoc)ci(dOrn)-NH2 121(KFmoc)ci(aAIB)-NH2 183(KFmoc)ci(aABA)-NH2 194(KFmoc)ci(Thiopro)-NH2 197(KFmoc)ci(Hyp)-NH2 205(KFmoc)ci(Nle)-NH2 267(KFmoc)ci(KFmoc)-NH2 356(KFmoc)ciX-NH2 412______________________________________
TABLE 18______________________________________HEMOLYTIC ACTIVITY OF (KFmoc)WKU-NH2 HD50 HD50 (μg/ml) (μg/ml)______________________________________(KFmoc)WKW-NH2 37 (KFmoc)WKc-NH2 25(KFmoc)WKC-NH2 43 (KFmoc)WKw-NH2 32(KFmoc)WKL-NH2 73 (KFmoc)WKf-NH2 126(KFmoc)WKM-NH2 102 (KFmoc)WKl-NH2 166(KFmoc)WKF-NH2 105 (KFmoc)WKm-NH2 178(KFmoc)WKV-NH2 137 (KFmoc)WKv-NH2 181(KFmoc)WKI-NH2 141 (KFmoc)WKs-NH2 296(KFmoc)WKY-NH2 156 (KFmoc)WKi-NH2 296(KFmoc)WKN-NH2 204 (KFmoc)WKh-NH2 313(KFmoc)WKS-NH2 206 (KFmoc)WKr-NH2 324(KFmoc)WKH-NH2 312 (KFmoc)WKy-NH2 368(KFmoc)WKT-NH2 367 (KFmoc)WKt-NH2 435(KFmoc)WKA-NH2 378 (KFmoc)WKa-NH2 437(KFmoc)WKR-NH2 387 (KFmoc)WKp-NH2 437(KFmoc)WKG-NH2 449 (KFmoc)WKq-NH2 483(KFmoc)WKK-NH2 469(KFmoc)WKX-NH2 209(KFmoc)WXX-NH2 64(KFmoc)WK(NO2 F)-NH2 67(KFmoc)WK(Nle)-NH2 91(KFmoc)WK(Nve)-NH2 98(KFmoc)WK(Thiopro)-NH2 108(KFmoc)WK(dOrn)-NH2 369(KFmoc)WK(MetO2)-NH2 437(KFmoc)WK(aAIB)-NH2 447(KFmoc)WK(aABA)-NH2 449______________________________________
TABLE 19______________________________________HEMOLYTIC ACTIVITY OF (KFmoc)WYZ-NH2 HD50 HD50 (μg/ml) (μg/ml)______________________________________(KFmoc)WYR-NH2 45 (KFmoc)WYs-NH2 27(KFmoc)WYK-NH2 65 (KFmoc)WYr-NH2 31(KFmoc)WYT-NH2 53 (KFmoc)WYt-NH2 37(KFmoc)WYP-NH2 97 (KFmoc)WYk-NH2 62(KFmoc)WYH-NH2 139 (KFmoc)WYh-NH2 73(KFmoc)WYC-NH2 267 (KFmoc)WYa-NH2 74(KFmoc)WYG-NH2 376 (KFmoc)WYp-NH2 76 (KFmoc)WYn-NH2 257(KFmoc)WYX-NH2 91(KFmoc)WXX-NH2 64(KFmoc)WY(Orn)-NH2 62(KFmoc)WY(dOrn)-NH2 67(KFmoc)WY(Hyp)-NH2 81(KFmoc)WY(aABA)-NH2 114(KFmoc)WY(Thiopro)-NH2 488______________________________________
TABLE 20______________________________________HEMOLYTIC ACTIVITY OF (KFmoc)WfZ-NH2______________________________________ HD50 HD50 (μg/ml) (μg/ml)______________________________________(KFmoc)WfP-NH2 40 (KFmoc)Wfw-NH2 36(KFmoc)WfY-NH2 42 (KFmoc)Wfr-NH2 42(KFmoc)WfR-NH2 122 (KFmoc)Wfp-NH2 65(KFmoc)WfI-NH2 208 (KFmoc)Wfl-NH2 197(KFmoc)WfL-NH2 294(KFmoc)WfX-NH2 128(KFmoc)WXX-NH2 64______________________________________ HD50 (μg/m)______________________________________(KFmoc)Wf(Hyp)-NH2 37(KFmoc)Wf(dOrn)-NH2 42(KFmoc)Wf(MetO2)-NH2 44(KFmoc)Wf(Thiopro)-NH2 45(KFmoc)Wf(KCBZ)-NH2 52(KFmoc)Wf(Orn)-NH2 64(KFmoc)Wf(aABA)-NH2 241(KFmoc)Wf(Bala)-NH2 360(KFmoc)Wf(aAIB)-NH2 383______________________________________
TABLE 21______________________________________HEMOLYTIC ACTIVITY OF (KFmoc)ciZ-NH2 HD50 HD50 (μg/ml) (μg/ml)______________________________________(KFmoc)ciP-NH2 27 (KFmoc)cip-NH2 39(KFmoc)ciT-NH2 29 (KFmoc)cit-NH2 48(KFmoc)ciG-NH2 35 (KFmoc)cir-NH2 48(KFmoc)ciQ-NH2 40 (KFmoc)cis-NH2 49(KFmoc)ciS-NH2 42 (KFmoc)cik-NH2 76(KFmoc)ciH-NH2 47 (KFmoc)cia-NH2 77(KFmoc)ciR-NH2 50 (KFmoc)ciq-NH2 195(KFmoc)ciA-NH2 68(KFmoc)ciK-NH2 79 (KFmoc)cin-NH2 317(KFmoc)ciL-NH2 97 (KFmoc)cih-NH2 382(KFmoc)ciN-NH2 116 (KFmoc)civ-NH2 439(KFmoc)ciW-NH2 283 (KFmoc)cii-NH2 443(KFmoc)ciF-NH2 295(KFmoc)ciM-NH2 386(KFmoc)ciV-NH2 391(KFmoc)ciC-NH2 400(KFmoc)ciX-NH2 92(KFmoc)cXX-NH2 108(KFmoc)ci(aAIB)-NH2 28(KFmoc)ci(aABA)-NH2 29(KFmoc)ci(Bala)-NH2 37(KFmoc)ci(Hyp)-NH2 39(KFmoc)ci(MetO2)-NH2 40(KFmoc)ci(KCBZ)-NH2 53(KFmoc)ci(gABA)-NH2 54(KFmoc)ci(Thiopro)-NH2 58(KFmoc)ci(Orn)-NH2 77(KFmoc)ci(dOrn)-NH2 77(KFmoc)ci(Cys ACM!)-NH2 84(KFmoc)ci(NO2 F)-NH2 363______________________________________
TABLE 22__________________________________________________________________________Biological activity of Ac-RRWWCO-NH2.Peptide IC50 (μg/ml) against % hemolysissequence S. aureus S. sanguis E. coli P. aeruginosa C. albicans at 100 μg/ml__________________________________________________________________________Ac-RRWWCA-NH2 35-40 60-70 21-23 97-98 193-210 2.2Ac-RRWWCC-NH2 47-63 92-94 54-68 86-88 162-166 9.5Ac-RRWWCD-NH2 >125 >500 >125 >500 >1000 0.3Ac-RRWWCE-NH2 >125 >500 >125 149 842-874 0.0Ac-RRWWCF-NH2 10-14 14-22 20-21 42-45 70-97 3.3Ac-RRWWCG-NH2 46-49 47-66 22-23 200 215-218 1.9Ac-RRWWCH-NH2 26-28 53-62 20-28 59-65 69-107 0.0Ac-RRWWCI-NH2 12-18 17-18 29-33 40-70 93-102 8.3Ac-RRWWCK-NH2 17-18 38-42 17-21 150 100-110 0.5Ac-RRWWCL-NH2 12-16 18-21 19-22 46-54 65-95 5.0Ac-RRWWCM-NH2 13-20 13-22 23-27 93-103 96-112 15Ac-RRWWCN-NH2 98-125 230 40-55 120 222-227 0.1Ac-RRWWCP-NH2 49-50 190 19-27 200 217-222 0.0Ac-RRWWCQ-NH2 52-98 230 41-42 60-65 223-230 0.0Ac-RRWWCR-NH2 11-12 22-45 12-18 87-130 100-101 0.0Ac-RRWWCS-NH2 41-44 54-59 20-21 290 211-213 1.8Ac-RRWWCT-NH2 38-47 56-61 24-28 180 216-223 0.5Ac-RRWWCV-NH2 19-21 41-46 17-18 33-44 103-174 0.0Ac-RRWWCW-NH2 41-43 55-78 58-61 60-88 151-166 14Ac-RRWWCY-NH2 12-28 59-60 20-21 97-110 184-212 5.8Ac-RRWWCX-NH2 25-30 51-58 21-28 70-87 181-219 11Ac-RRWWXX-NH2 32-33 36-51 31-37 93-125 195-204 1.6Ac-RRWXXX-NH2 130 115 100 >500 294-297 0.0Ac-RRXXXX-NH2 1913 >2500 935 >500 >2500 0.0__________________________________________________________________________ X represents an equimolar mixture of 19 of the 20 natural Lamino acids, cysteine being excluded. The greatest activities are represented in bold characters.
TABLE 23__________________________________________________________________________Biological activity of all -D-amino acid peptides and of naturallyoccurring peptidesPeptide IC50 (μg/ml) against % hemolysissequence S. aureus S. sanguis E. coli P. aeruginosa C. albicans at 100 μg/ml__________________________________________________________________________Ac-rrwwcr-NH2 9-13 14-15 10-11 28-29 68-78 2.0Ac-rrwwcv-NH2 16-19 7-8 9-10 58-88 107-119 10.0MagaininII-NH2 32-64 143-235 72-98 150-200 41-42Cecropin A >500 337-400 1-2 5-6 81-88 0.0__________________________________________________________________________
EXAMPLE II
PEPTIDES HAVING ANTI-MELLITIN ACTIVITY
A. Positional Scanning Synthetic Peptide Combinatorial Libraries
A Positional Scanning Synthetic Peptide Combinational Library (SPCL) was prepared as described in C. Pinilla et al., Biotechniques, 13, p. 901 (1992). The six individual positional peptide libraries making up the positional scanning SPCL were prepared by previously described methods. Houghten et al., BioTechniques 13:412-421 (1992); Houghten et al., In T. Shiba and S. Sakakibara (Eds.), Peptide Chemistry, Protein Rsearch Foundation, Osaka 769-774 (1988); Houghten et al., Nature 354:84-86 (1991). Each of the six peptide libraries was composed of 18 peptide mixtures in which a single position was defined (represented by O) with one of 18 of the 20 natural L-amino acids (cysteine and tryptophan were omitted), and the remaining five positions of the six-residue sequence were composed of mixtures (represented by X) of the same 18 amino acids. The six positional peptide libraries differed only in the location of the defined position. They were represented as Ac-O1 XXXXX-NH2, Ac-XO2 XXXX-NH2, Ac-XXO3 XXX-NH2, Ac-XXXO4 XX-NH2, Ac-XXXXO5 X-NH2 and Ac-XXXXXO6 -NH2 wherein O represented a fixed amino acid of choice and X represented an equimolar mixture of selected amino acids (108 peptide mixtures in total). Since each peptide mixture represented 1,889,568 (185) individual sequences, each of the six positional peptide libraries contained in total 34,012,224 (18×1,889, 568) different hexamers. Although each of the six positional SPCLs could be examined independently, this set of 108 peptide mixtures, when used in concert, yielded a positional scanning SPCL (PS-SPCL).
The peptide mixture resins which made up the PS-SPCL were prepared using chemical mixtures (i.e., a specific ratio of a mixture of amino acids. Houghten et al., In T. Shiba and S. Sakakibara (Eds.), Peptide Chemistry, Protein Rsearch Foundation, Osaka 769-774 (1988). Amino acid analysis, using the physically divided, coupled and recombined mixture resins as a control (Houghten et al., Nature 354:84-86 (1991) showed the presence of each amino acid in approximately equimolar concentration (±25%). The cleavage and extraction of peptide mixtures from the resin were carried out as described earlier for other SPCLs. Houghten et al., BioTechniques 13:412-421 (1992); Houghten et al., Nature 354:84-86 (1991).
B. Mellitin Inhibition Assay
Each assay was carried out in 96-well tissue culture plates. Four wells per plate contained 125 μl of a non-peptide control (1% Triton in deionized water), and four wells per plate contained 125 μl of a control blank, phosphate buffered saline (PBS). Uninhibited melittin was used as a comparative control. The controls served to detect possible contamination and to calculate the percent inhibition of each peptide. Human red blood cells (RBCs) were washed with PBS and centrifuged to separate them from the serum. RBCs were then resuspended in PBS to a final suspension of 0.5% RBCs. Peptides were added to the plate in duplicate and in 60 μl increments (5 μl of 10X PBS was added to salinate the aqueous peptides). The concentration necessary to inhibit 50% of the lysis of RBCs by melittin (IC50), was determined by performing a serial two-fold dilution of the peptide ranging from 1000 μg/ml to 3.91 μg/ml. After peptides were prepared in the proper dilutions on the plate, 60 μl of a 30 μg/ml melittin solution in PBS were added to all wells containing peptide. 125 μl of the blood suspension was added to all the wells and the plates were incubated at 37° C. for one hour. They were then centrifuged at 2800 rpm for five minutes and the release of hemoglobin resulting from the cell lysis was determined by measuring the OD at 414 nm of 100 μl of the supernatant.
C. Results
An SPCL consisting of 400 different six-residue peptide mixtures (a total of 52,128,400 individual peptides) having acetylated N-terminals and amidated C-terminals was screened in a competition type hemolytic assay (i.e., competing melittin (7.5 μg/ml-2.6 μM); each individual peptide mixture was screened in the presence of 0.25% red blood cells (RBCs) in phosphate buffered saline). Each of the 400 peptide mixtures was represented by the formula Ac-O1 O2 XXXX-NH2, where O1 and O1 and O2 represented each of the 20 natural L-amino acids and X represented an equimolar mixture of 19 of the 20 natural L-amino acids (cysteine omitted).
Ac-IVXXXX-NH2 was one of the most active peptide mixtures found in this SPCL, and was followed to a final sequence as illustrated here. The four subsequent X positions were defined using an iterative process (R. A. Houghten et al., Nature, 354(1991). R. A. Houghten et al., BioTechniques, (1992) v. 13, pp. 412-421 in press.) involving synthesis, screening, and selection.
Hydrophobic character appears to be required for the peptide inhibitors of melittin. The activity of these peptides decreased as the concentration of melittin increased. These results suggest a mechanism of inhibition involving hydrophobic interactions between the peptides and melittin that prevent melittin from interacting with the membrane, and, in turn, lysing RBCs.
Tables 24 to 27 show the anti-melittin activity of various peptides. "X" refers to an equimolar mixture of the 19 naturally occuring L-amino acids (cysteine omitted).
TABLE 24______________________________________Inhibition of melittin by Ac-IVILTZ-NH2 IC50 (μg/ml)______________________________________Ac-IVILTM-NH2 9Ac-IVILTF-NH2 10Ac-IVILTL-NH2 10Ac-IVILTQ-NH2 11Ac-IVILTW-NH2 11Ac-IVILTA-NH2 13Ac-IVILTN-NH2 14Ac-IVILTX-NH2 16Ac-IVILTY-NH2 18Ac-IVILTC-NH2 19Ac-IVILTV-NH2 21Ac-IVILTG-NH2 22Ac-IVILTE-NH2 24Ac-IVILTS-NH2 36Ac-IVILTT-NH2 44Ac-IVILTP-NH2 49Ac-IVILTH-NH2 56Ac-IVILTI-NH2 >250Ac-IVILTK-NH2 >250Ac-IVILTR-NH2 >250______________________________________
TABLE 25______________________________________Inhibition of melittin by Ac-IVILLZ-NH2 IC50 (μg/ml)______________________________________Ac-IVILLW-NH2 5Ac-IVILLE-NH2 8Ac-IVILLQ-NH2 9Ac-IVILLY-NH2 10Ac-IVILLN-NH2 13Ac-IVILLX-NH2 13Ac-IVILLS-NH2 15Ac-IVILLA-NH2 15Ac-IVILLG-NH2 17Ac-IVILLD-NH2 18Ac-IVILLT-NH2 18Ac-IVILLM-NH2 20Ac-IVILLF-NH2 21Ac-IVILLP-NH2 26Ac-IVILLI-NH2 26Ac-IVILLV-NH2 70Ac-IVILLL-NH2 89Ac-IVILLC-NH2 >250Ac-IVILLH-NH2 >250Ac-IVILLK-NH2 >250Ac-IVILLR-NH2 >250______________________________________
TABLE 26______________________________________Melittin inhibition by Ac-IVIFFZ-NH2 IC50 (μg/ml)______________________________________Ac-IVIFFD-NH2 10Ac-IVIFFE-NH2 14Ac-IVIFFW-NH2 16Ac-IVIFFN-NH2 18Ac-IVIFFM-NH2 21Ac-IVIFFY-NH2 21Ac-IVIFFS-NH2 21Ac-IVIFFX-NH2 22Ac-IVIFFG-NH2 22Ac-IVIFFT-NH2 24Ac-IVIFFA-NH2 25Ac-IVIFFQ-NH2 26Ac-IVIFFV-NH2 30Ac-IVIFFH-NH2 30Ac-IVIFFP-NH2 38Ac-IVIFFC-NH2 72Ac-IVIFFI-NH2 83Ac-IVIFFL-NH2 111Ac-IVIFFF-NH2 169Ac-IVIFFK-NH2 >250Ac-IVIFFR-NH2 >250______________________________________
TABLE 27______________________________________Inhibition of melittin by individual peptidesderived from PS-SPCL IC50 (μg/ml)______________________________________NDEIVI-NH2 311NEEIVI-NH2 364NDEIVF-NH2 627NEEIVF-NH2 905DDEITF-NH2 1201Ac-FIIWCE-NH2 3.4Ac-IIIWCE-NH2 4.5Ac-FIIYCE-NH2 4.7Ac-IQIYCE-NH2 4.8Ac-IIIYFE-NH2 4.9Ac-IIIWFE-NH2 5.4Ac-FIIWFE-NH2 5.4Ac-IQIWCE-NH2 5.6Ac-FIIYFE-NH2 6.8Ac-FQIWFE-NH2 8.2Ac-FQIWCE-NH2 9.4Ac-IIIYCE-NH2 12Ac-FQIYCE-NH2 14Ac-IQIYFE-NH2 17Ac-FQIYFE-NH2 19Ac-IQIWFE-NH2 21Ac-IDIWCK-NH2 106Ac-FDIWFK-NH2 115Ac-FDIWFE-NH2 166Ac-FDIYCE-NH2 190Ac-IDIYCE-NH2 287Ac-IDIYFE-NH2 298Ac-FIIYFK-NH2 365Ac-IDIYFK-NH2 770Ac-IDIWCE-NH2 801Ac-FDIYFE-NH2 922Ac-IQIYCK-NH2 1061Ac-FIIWFK-NH2 1298Ac-MILWIE-NH2 11Ac-VIQQFE-NH2 16Ac-WIQIFI-NH2 22______________________________________
EXAMPLE III
ALL D-AMINO ACID PEPTIDES HAVING TRYPSIN INHIBITING ACTIVITY
A. Synthetic Peptide Libraries
A positional scanning synthetic peptide combinatorial library (PS-SPCL), represented by the formulas Ac-oxxxxx-NH2, Ac-xoxxxx-NH2, Ac-xxoxxx-NH2, Ac-xxxoxx-NH2, Ac-xxxxox-NH2 and Ac-xxxxxo-NH2, was generated as described earlier (C. Pinilla, et. al., (1992) BioTechniques 13:901-905). Each of the sequences listed above represents twenty peptide mixtures in which o represents positions occupied by one of the 19 D-amino acids or glycine, and x represents positions occupied by a mixture of 18 of the 19 D-amino acids (cysteine excluded), and glycine. The x positions were incorporated by coupling of a mixture of 18 of the 19 D-amino acids (cysteine excluded) and glycine. The molar ratio of the amino acids in the mixture was the same as established for the coupling of mixtures of L-amino acids (Dooley, C. & Houghten, R. A. (1993) Life Science 52:1509-1517).
The peptide mixtures represented by the formulas Ac-ryoxxx-NH2, Ac-ryroxx-NH2 and Ac-ryrpox-NH2 were synthesized using the DCR (divide, couple, recombine) process (Boughten, R. A., et al., Nature 354:84-86 (1991)). The individual peptides represented by the formula Ac-ryrpwo-NH2 were synthesized using the method of simultaneous multiple peptide synthesis (SMPS) (Houghten, R. A. (1985) Proc.Natl.Acad. Sci. U.S.A. 82:5131-5135; U.S. Pat. No. 4,631,211).
B. Trypsin Inhibition Assay
The assay was performed in a 96-well assay plate, 15 μl trypsin (from bovine pancreas, 8,600 units/mg solid) solution (0.05 mg/ml 0.02M HCl), 50 μl peptide solution (1 to 3 mM in water), and 100 μl 10.1M Tris-buffer containing 25 mM CaCl2 (pH 7.8) were mixed in the wells of the assay plate. After incubation for 30 minutes, 100 μl substrate solution (N.sup.α -benzoyl-DL-arginine-p-nitroanilide, 2.3 mM in water) was added. After 30 minutes, absorbances were read at 405 nm using a Titertek multichannel photometer, and expressed as a percentage of the control (well without peptide). The values obtained with serial dilutions of the peptide solutions were used to determine the IC50 values (concentration neccessary for 50% inhibition).
C. Results
The 20 individual peptides, represented by the formula Ac-ryrpwo-NH2, were synthesized and screened. The peptides with the highest trypsin inhibiting activity (IC50 less than 150 μM) are listed in Table 28.
TABLE 28______________________________________Trypsin inhibiting activity of all D-amino acid peptideswith IC50 less than 150 μMpeptide IC50 μM!______________________________________Ac-ryrpwp-NH2 62Ac-ryrpww-NH2 125Ac-ryrpwv-NH2 131Ac-ryrpwc-NH2 135Ac-ryrpwt-NH2 142______________________________________
Although the invention has been described with reference to the presently-preferred embodiments, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.
__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 15(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 4 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /label=Xaa/note="Xaa=KFmoc"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 2..4(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 4(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:XaaXaaXaaXaa(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 4 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /label=Xaa/note="Xaa=KFmoc"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 3..4(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 4(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:XaaTrpXaaXaa1(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 4 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /label=Xaa/note="Xaa=KFmoc"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 4(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 4(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:XaaTrpLysXaa1(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 4 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /label=Xaa/note="Xaa=KFmoc"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 4(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 4(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:XaaTrpTyrXaa1(2) INFORMATION FOR SEQ ID NO:5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 5..6(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:ArgArgTrpTrpXaaXaa15(2) INFORMATION FOR SEQ ID NO:6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:ArgArgTrpTrpCysXaa15(2) INFORMATION FOR SEQ ID NO:7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 26(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:GlyIleGlyAlaValLeuLysValLeuThrThrGlyLeuProAlaLeu151015IleSerTrpIleLysArgLysArgGlnGln2025(2) INFORMATION FOR SEQ ID NO:8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 5..6(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:IleValIleLeuXaaXaa15(2) INFORMATION FOR SEQ ID NO:9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:IleValIleLeuThrXaa15(2) INFORMATION FOR SEQ ID NO:10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:IleValIleLeuLeuXaa15(2) INFORMATION FOR SEQ ID NO:11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /label=Xaa/note="Xaa=any amino acid"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:IleValIlePhePheXaa15(2) INFORMATION FOR SEQ ID NO:12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /label=Xaa/note="Xaa=Phe or Ile"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 2(D) OTHER INFORMATION: /label=Xaa/note="Xaa=Ile, Gln or Asp"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 4(D) OTHER INFORMATION: /label=Xaa/note="Xaa=Trp or Tyr"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 5(D) OTHER INFORMATION: /label=Xaa/note="Xaa=Cys or Phe"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /label=Xaa/note="Xaa=Glu or Lys"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:XaaXaaIleXaaXaaXaa15(2) INFORMATION FOR SEQ ID NO:13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:MetIleLeuTrpIleGlu15(2) INFORMATION FOR SEQ ID NO:14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:ValIleGlnGlnPheVal15(2) INFORMATION FOR SEQ ID NO:15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 6 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 1(D) OTHER INFORMATION: /note="N-terminal amino acid isacetylated"(ix) FEATURE:(A) NAME/KEY: Modified-site(B) LOCATION: 6(D) OTHER INFORMATION: /note="C-terminal amino acid isamidated"(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:TrpIleGlnIlePheIle15__________________________________________________________________________
| 标题 | 发布/更新时间 | 阅读量 |
|---|---|---|
| 一种低溶血活性的蜂毒肽及其应用 | 2020-05-08 | 311 |
| 一种突变蜂毒肽MEL-pep及其应用 | 2020-05-08 | 265 |
| 制备去除过敏成分的精制蜂毒的方法及通过所述方法制备的去除过敏成分的精制蜂毒 | 2020-05-15 | 716 |
| 一种活蜂蜂毒采集和蜂毒重量检测的方法及装置 | 2020-05-08 | 286 |
| 一种蜂毒溶血肽隐蔽溶血毒副作用的方法 | 2020-05-11 | 175 |
| 貉细小病毒性肠炎、犬瘟热二联灭活疫苗及其制备方法 | 2020-05-13 | 10 |
| 草本养护膏 | 2020-05-12 | 604 |
| Y型多功能靶向多肽及其在构建肿瘤靶向递药系统中的应用 | 2020-05-15 | 390 |
| A7R糖肽及其在制备肿瘤诊治药物中的用途 | 2020-05-11 | 787 |
| 抗IgE抗体 | 2020-05-14 | 942 |
高效检索全球专利专利汇是专利免费检索,专利查询,专利分析-国家发明专利查询检索分析平台，是提供专利分析，专利查询，专利检索等数据服务功能的知识产权数据服务商。
我们的产品包含105个国家的1.26亿组数据，免费查、免费专利分析。
专利汇分析报告产品可以对行业情报数据进行梳理分析，涉及维度包括行业专利基本状况分析、地域分析、技术分析、发明人分析、申请人分析、专利权人分析、失效分析、核心专利分析、法律分析、研发重点分析、企业专利处境分析、技术处境分析、专利寿命分析、企业定位分析、引证分析等超过60个分析角度，系统通过AI智能系统对图表进行解读，只需1分钟，一键生成行业专利分析报告。
-
7 METHODS
